BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2:19-76. [PMID: 779020 DOI: 10.1093/schbul/2.1.19] [Cited by in Crossref: 583] [Cited by in F6Publishing: 456] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Megens AAHP, Niemegeers CJE, Awouters FHL. Antipsychotic profile and side-effect liability of haloperidol, risperidone, and ocaperidone as predicted from their differential interaction with amphetamine in rats. Drug Dev Res 1992;26:129-45. [DOI: 10.1002/ddr.430260203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
2 Ocklenburg S, Arning L, Gerding WM, Epplen JT, Güntürkün O, Beste C. Cholecystokinin A receptor (CCKAR) gene variation is associated with language lateralization. PLoS One 2013;8:e53643. [PMID: 23341962 DOI: 10.1371/journal.pone.0053643] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
3 Lawson WB, Karson CN, Bigelow LB. Increased urine volume in chronic schizophrenic patients. Psychiatry Res 1985;14:323-31. [PMID: 3860885 DOI: 10.1016/0165-1781(85)90100-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
4 Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Med Hypotheses 2015;85:391-6. [PMID: 26118462 DOI: 10.1016/j.mehy.2015.06.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
5 Altar C, Boyar W. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin. Brain Research 1989;483:321-6. [DOI: 10.1016/0006-8993(89)90176-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 1.3] [Reference Citation Analysis]
6 Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91:415-33. [PMID: 2884687 DOI: 10.1007/BF00216006] [Cited by in Crossref: 336] [Cited by in F6Publishing: 87] [Article Influence: 9.9] [Reference Citation Analysis]
7 Udawela M, Scarr E, Hannan AJ, Thomas EA, Dean B. Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. Aust N Z J Psychiatry 2011;45:140-7. [PMID: 21091263 DOI: 10.3109/00048674.2010.533364] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
8 Gracey DJ, Bell R, King DJ, Trimble KM, McDermott BJ. Enhancement of latent inhibition in the rat by the CCK antagonist proglumide. Pharmacol Biochem Behav 1998;59:1053-9. [PMID: 9586867 DOI: 10.1016/s0091-3057(97)00533-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Merchant KM, Miller MA, Ashleigh EA, Dorsa DM. Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain. Brain Research 1991;540:311-4. [DOI: 10.1016/0006-8993(91)90526-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 1.7] [Reference Citation Analysis]
10 Acharya S, Kim KM. Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease. Int J Mol Sci 2021;22:4299. [PMID: 33919025 DOI: 10.3390/ijms22094299] [Reference Citation Analysis]
11 Howell KR, Law AJ. Neurodevelopmental concepts of schizophrenia in the genome-wide association era: AKT/mTOR signaling as a pathological mediator of genetic and environmental programming during development. Schizophr Res 2020;217:95-104. [PMID: 31522868 DOI: 10.1016/j.schres.2019.08.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Nemeroff CB, Luttinger D. The anhedonia hypothesis of neuroleptic drug action: Basic and clinical considerations. Behav Brain Sci 1982;5:70-1. [DOI: 10.1017/s0140525x00010554] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
13 Csernansky J, Glick S, Mellentin J. Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function. Psychopharmacology 1987;91:440-4. [DOI: 10.1007/bf00216008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Maas JW, Hattox SE, Martin DM, Landis DH. A DIRECT METHOD FOR DETERMINING DOPAMINE SYNTHESIS AND OUTPUT OF DOPAMINE METABOLITES FROM BRAIN IN AWAKE ANIMALS. J Neurochem 1979;32:839-43. [DOI: 10.1111/j.1471-4159.1979.tb04568.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 1.1] [Reference Citation Analysis]
15 Dahoun T, Pardiñas AF, Veronese M, Bloomfield MAP, Jauhar S, Bonoldi I, Froudist-Walsh S, Nosarti C, Korth C, Hennah W, Walters J, Prata D, Howes OD. The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study. Hum Mol Genet 2018;27:3498-506. [PMID: 29945223 DOI: 10.1093/hmg/ddy242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Hansen N. Locus Coeruleus Malfunction Is Linked to Psychopathology in Prodromal Dementia With Lewy Bodies. Front Aging Neurosci 2021;13:641101. [PMID: 33732141 DOI: 10.3389/fnagi.2021.641101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dolleman-van der Weel MJ, Witter MP. The thalamic midline nucleus reuniens: potential relevance for schizophrenia and epilepsy. Neurosci Biobehav Rev 2020;119:422-39. [PMID: 33031816 DOI: 10.1016/j.neubiorev.2020.09.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Kubota M, Nagashima T, Takano H, Kodaka F, Fujiwara H, Takahata K, Moriguchi S, Kimura Y, Higuchi M, Okubo Y, Takahashi H, Ito H, Suhara T. Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia. Int J Neuropsychopharmacol. 2017;20:928-935. [PMID: 29016872 DOI: 10.1093/ijnp/pyx063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
19 Lambert G, Eisenhofer G, Cox H, Horne M, Kalff V, Kelly M, Jennings G, Esler M. Direct determination of homovanillic acid release from the human brain, and indicator of central dopaminergic activity. Life Sciences 1991;49:1061-72. [DOI: 10.1016/0024-3205(91)90593-z] [Cited by in Crossref: 63] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
20 Meltzer H, Simonovic M, Fang V, Piyakalamala S, Young M. A comparison of the effects of anti-psychotic drugs on pituitary, striatal and limbic system post-synaptic dopamine receptors. Life Sciences 1978;23:605-9. [DOI: 10.1016/0024-3205(78)90040-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 0.7] [Reference Citation Analysis]
21 Stahl SM. Needs and opportunities for innovation in psychopharmacology. J R Soc Med 1987;80:413-7. [PMID: 3656311 DOI: 10.1177/014107688708000707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
22 Wenthur CJ, Lindsley CW. Classics in chemical neuroscience: clozapine. ACS Chem Neurosci 2013;4:1018-25. [PMID: 24047509 DOI: 10.1021/cn400121z] [Cited by in Crossref: 70] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
23 Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52. [PMID: 2905529 DOI: 10.1002/syn.890010203] [Cited by in Crossref: 585] [Cited by in F6Publishing: 485] [Article Influence: 18.3] [Reference Citation Analysis]
24 Dandash O, Pantelis C, Fornito A. Dopamine, fronto-striato-thalamic circuits and risk for psychosis. Schizophr Res 2017;180:48-57. [PMID: 27595552 DOI: 10.1016/j.schres.2016.08.020] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 7.8] [Reference Citation Analysis]
25 Csernansky JG, Mellentin J, Beauclair L, Lombrozo L. Mesolimbic dopaminergic supersensitivity following electrical kindling of the amygdala. Biological Psychiatry 1988;23:285-94. [DOI: 10.1016/0006-3223(88)90039-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
26 Cesarec Z, Nyman AK. Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand 1985;71:523-38. [DOI: 10.1111/j.1600-0447.1985.tb05066.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
27 Carlsson A. Does dopamine play a role in schizophrenia? Psychol Med 1977;7:583-97. [DOI: 10.1017/s003329170000622x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 23] [Article Influence: 9.9] [Reference Citation Analysis]
28 Tuplin EW, Holahan MR. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Curr Neuropharmacol 2017;15:1192-207. [PMID: 28412910 DOI: 10.2174/1570159X15666170413115754] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 7.7] [Reference Citation Analysis]
29 Szymanski HV, Orfanos A, Narisawa K, Grosz R, Naylor EW. Dihydropteridine reductase in schizophrenic patients. Psychiatry Res 1985;15:115-9. [PMID: 3862143 DOI: 10.1016/0165-1781(85)90047-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
30 Goldstein JM, Link BG. Gender and the expression of schizophrenia. Journal of Psychiatric Research 1988;22:141-55. [DOI: 10.1016/0022-3956(88)90078-7] [Cited by in Crossref: 159] [Cited by in F6Publishing: 136] [Article Influence: 4.8] [Reference Citation Analysis]
31 Solomon PR, Crider A. Attention, dopamine, and schizophrenia. Behav Brain Sci 1982;5:75-6. [DOI: 10.1017/s0140525x00010591] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
32 Perogamvros L, Schwartz S. The roles of the reward system in sleep and dreaming. Neurosci Biobehav Rev 2012;36:1934-51. [PMID: 22669078 DOI: 10.1016/j.neubiorev.2012.05.010] [Cited by in Crossref: 101] [Cited by in F6Publishing: 71] [Article Influence: 11.2] [Reference Citation Analysis]
33 Dotti A, Lostia O, Rubino IA, Bersant G, Carilli L, Zorretta D. The prolactin response in patients receiving neuroleptic therapy. The effect of fluphenazine decanoate. Progress in Neuro-Psychopharmacology 1981;5:69-77. [DOI: 10.1016/0364-7722(81)90007-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
34 Rubin RT, Hays SE. The prolactin secretory response to neuroleptic drugs: Mechanisms, applications and limitations. Psychoneuroendocrinology 1980;5:121-37. [DOI: 10.1016/0306-4530(80)90015-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 1.0] [Reference Citation Analysis]
35 Van Ree JM, De Wied D. Brain Peptides and Psychoactive Drug Effects. In: Israel Y, Glaser FB, Kalant H, Popham RE, Schmidt W, Smart RG, editors. Research Advances in Alcohol and Drug Problems. Boston: Springer US; 1981. pp. 67-105. [DOI: 10.1007/978-1-4615-7740-9_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
36 Gotoh L, Mitsuyasu H, Kobayashi Y, Oribe N, Takata A, Ninomiya H, Stanton VP Jr, Springett GM, Kawasaki H, Kanba S. Association analysis of adenosine A1 receptor gene (ADORA1) polymorphisms with schizophrenia in a Japanese population. Psychiatr Genet 2009;19:328-35. [PMID: 19820430 DOI: 10.1097/YPG.0b013e3283328e26] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
37 Gioanni Y, Thierry A, Glowinski J, Tassin J. ?1-adrenergic, D1, and D2 receptors interactions in the prefrontal cortex: Implications for the modality of action of different types of neuroleptics. Synapse 1998;30:362-70. [DOI: 10.1002/(sici)1098-2396(199812)30:4<362::aid-syn3>3.0.co;2-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
38 Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA. Abolition of latent inhibition by a single 5 mg dose ofd-amphetamine in man. Psychopharmacology 1992;107:425-30. [DOI: 10.1007/bf02245170] [Cited by in Crossref: 207] [Cited by in F6Publishing: 18] [Article Influence: 7.1] [Reference Citation Analysis]
39 Gebhardt S, Grant P, von Georgi R, Huber MT. Aspects of Piaget's cognitive developmental psychology and neurobiology of psychotic disorders - an integrative model. Med Hypotheses 2008;71:426-33. [PMID: 18524496 DOI: 10.1016/j.mehy.2008.03.042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
40 Kambeitz J, Abi-Dargham A, Kapur S, Howes OD. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry 2014;204:420-9. [PMID: 25029687 DOI: 10.1192/bjp.bp.113.132308] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 12.8] [Reference Citation Analysis]
41 Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11:59-67. [PMID: 21420906 DOI: 10.1016/j.coph.2011.02.007] [Cited by in Crossref: 231] [Cited by in F6Publishing: 174] [Article Influence: 23.1] [Reference Citation Analysis]
42 Tejedor-Real P, Faucon Biguet N, Dumas S, Mallet J. Tyrosine hydroxylase mRNA and protein are down-regulated by chronic clozapine in both the mesocorticolimbic and the nigrostriatal systems. J Neurosci Res 2003;72:105-15. [PMID: 12645084 DOI: 10.1002/jnr.10555] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
43 Weinberger DR, Wyatt RJ. Enlarged Cerebral Ventricles in Schizophrenia. Psychiatric Annals 1983;13:412-8. [DOI: 10.3928/0048-5713-19830501-06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
44 Gulya K. The opioid system in neurologic and psychiatric disorders and in their experimental models. Pharmacology & Therapeutics 1990;46:395-428. [DOI: 10.1016/0163-7258(90)90026-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Reisine T. Adaptive changes in catecholamine receptors in the central nervous system. Neuroscience 1981;6:1471-502. [PMID: 6115335 DOI: 10.1016/0306-4522(81)90221-9] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 2.5] [Reference Citation Analysis]
46 Mewshaw RE, Nelson JA, Shah US, Shi X, Mazandarani H, Coupet J, Marquis K, Brennan JA, Andree TH. New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorganic & Medicinal Chemistry Letters 1999;9:2593-8. [DOI: 10.1016/s0960-894x(99)00434-5] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
47 Iwatani J, Ishida T, Donishi T, Ukai S, Shinosaki K, Terada M, Kaneoke Y. Use of T1-weighted/T2-weighted magnetic resonance ratio images to elucidate changes in the schizophrenic brain. Brain Behav 2015;5:e00399. [PMID: 26516617 DOI: 10.1002/brb3.399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
48 Gray JA, Joseph MH, Hemsley DR, Young AM, Clea Warburton E, Boulenguez P, Grigoryan GA, Peters SL, Rawlins J, Taib C, Yee B, Cassaday H, Weiner I, Gal G, Gusak O, Joel D, Shadach E, Shalev U, Tarrasch R, Feldon J. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behavioural Brain Research 1995;71:19-IN3. [DOI: 10.1016/0166-4328(95)00154-9] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 4.5] [Reference Citation Analysis]
49 Sommer BR, Wise LC, Kraemer HC. Is dopamine administration possibly a risk factor for delirium?: . Critical Care Medicine 2002;30:1508-11. [DOI: 10.1097/00003246-200207000-00019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
50 van Ruitenbeek P, Mehta MA. Potential enhancing effects of histamine H₁ agonism/H₃ antagonism on working memory assessed by performance and bold response in healthy volunteers. Br J Pharmacol 2013;170:144-55. [PMID: 23517178 DOI: 10.1111/bph.12184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Rebec GV, Bashore TR. Critical issues in assessing the behavioral effects of amphetamine. Neurosci Biobehav Rev 1984;8:153-9. [PMID: 6145135 DOI: 10.1016/0149-7634(84)90030-7] [Cited by in Crossref: 115] [Cited by in F6Publishing: 78] [Article Influence: 3.1] [Reference Citation Analysis]
52 Castellani S, Adams PM. Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. European Journal of Pharmacology 1981;73:143-54. [DOI: 10.1016/0014-2999(81)90086-8] [Cited by in Crossref: 114] [Cited by in F6Publishing: 99] [Article Influence: 2.9] [Reference Citation Analysis]
53 Garbutt JC, van Kammen DP, Levine RA, Sternberg DE, Murphy DL, Ballenger J, Bunney WE, Lovenberg WM. Cerebrospinal fluid hydroxylase cofactor in schizophrenia. Psychiatry Research 1982;6:145-51. [DOI: 10.1016/0165-1781(82)90002-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
54 Erard R, Luisada PV, Peele R. The PCP Psychosis: Prolonged Intoxication or Drug-Precipitated Functional Illness? Journal of Psychedelic Drugs 2012;12:235-51. [DOI: 10.1080/02791072.1980.10471432] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
55 Krieger NR, Megill JR, Sterling P. Granule cells in the rat olfactory tubercle accumulate 3H-gamma-aminobutyric acid. J Comp Neurol 1983;215:465-71. [PMID: 6134758 DOI: 10.1002/cne.902150410] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
56 Mazhar F, Battini V, Pozzi M, Invernizzi E, Mosini G, Gringeri M, Capuano A, Scavone C, Radice S, Clementi E, Carnovale C. Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review. Int J Neuropsychopharmacol 2021;24:477-89. [PMID: 33575781 DOI: 10.1093/ijnp/pyab005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
57 Schlemmer RF, Davis JM. Evidence for Dopamine Mediation of Submissive Gestures in the Stumptail Macaque Monkey. Pharmacology Biochemistry and Behavior 1981;14:95-102. [DOI: 10.1016/s0091-3057(81)80016-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
58 Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2010;11:256-61. [PMID: 20218790 DOI: 10.3109/15622970802309617] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
59 Ashby CR, Wang RY. Effects of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex: microiontophoretic studies. Brain Research 1990;506:346-8. [DOI: 10.1016/0006-8993(90)91278-o] [Cited by in Crossref: 35] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
60 Nisoli E, Grilli M, Memo M, Missale C, Spano P. Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. I. Frontal cortex. Neuroscience Letters 1988;87:247-52. [DOI: 10.1016/0304-3940(88)90456-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
61 Alcaro A, Panksepp J. The SEEKING mind: Primal neuro-affective substrates for appetitive incentive states and their pathological dynamics in addictions and depression. Neuroscience & Biobehavioral Reviews 2011;35:1805-20. [DOI: 10.1016/j.neubiorev.2011.03.002] [Cited by in Crossref: 126] [Cited by in F6Publishing: 88] [Article Influence: 12.6] [Reference Citation Analysis]
62 Davidson M, Kendler KS, Mohs RC, Hollander E, Ryan T, Davis KL. Effect of apomorphine infusion on plasma homovanillic acid in normal subjects. Journal of Psychiatric Research 1986;20:131-5. [DOI: 10.1016/0022-3956(86)90012-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
63 Csernansky JG, Wrona CT, Bardgett ME, Early TS, Newcomer JW. Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics. Psychopharmacology 1993;110:145-51. [DOI: 10.1007/bf02246964] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Baker GB, Greenshaw AJ. Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell Mol Neurobiol 1989;9:1-44. [DOI: 10.1007/bf00711441] [Cited by in Crossref: 82] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
65 Antelman SM, Caggiula AR. Stress-Induced Behavior: Chemotherapy without Drugs. In: Davidson JM, Davidson RJ, editors. The Psychobiology of Consciousness. Boston: Springer US; 1980. pp. 65-104. [DOI: 10.1007/978-1-4684-3456-9_4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
66 Kulkarni J, Keks NA, Stuart G, Mackie B, Minas IH, Singh BS, Copolov DL. Relationship of psychotic symptoms to haloperidol-stimulated prolactin release. Acta Psychiatr Scand 1990;82:271-4. [DOI: 10.1111/j.1600-0447.1990.tb01383.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
67 Ettenberg A. Behavioral effects of neuroleptics: Performance deficits, reward deficits or both? Behav Brain Sci 1982;5:56-7. [DOI: 10.1017/s0140525x00010414] [Cited by in Crossref: 13] [Article Influence: 1.2] [Reference Citation Analysis]
68 Nielsen EB, Nielsen M, Ellison G, Braestrup C. Decreased spiroperidol and LSD binding in rat brain after continuous amphetamine. European Journal of Pharmacology 1980;66:149-54. [DOI: 10.1016/0014-2999(80)90137-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 1.0] [Reference Citation Analysis]
69 Wise RA. Neuroleptics and operant behavior: The anhedonia hypothesis. Behav Brain Sci 1982;5:39-53. [DOI: 10.1017/s0140525x00010372] [Cited by in Crossref: 757] [Article Influence: 68.8] [Reference Citation Analysis]
70 Takahashi T, Suzuki M, Tsunoda M, Kawamura Y, Takahashi N, Maeno N, Kawasaki Y, Zhou SY, Hagino H, Niu L, Tsuneki H, Kobayashi S, Sasaoka T, Seto H, Kurachi M, Ozaki N. The association of genotypic combination of the DRD3 and BDNF polymorphisms on the adhesio interthalamica and medial temporal lobe structures. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1236-42. [PMID: 18472202 DOI: 10.1016/j.pnpbp.2008.03.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
71 Gründer G, Cumming P. The Dopamine Hypothesis of Schizophrenia. The Neurobiology of Schizophrenia. Elsevier; 2016. pp. 109-24. [DOI: 10.1016/b978-0-12-801829-3.00015-x] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
72 Luchins DJ, Robertson AG, Meltzer HY. Serum prolactin, psychopathology, and ventricular size in chronic schizophrenia. Psychiatry Res 1984;12:149-53. [PMID: 6147869 DOI: 10.1016/0165-1781(84)90014-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
73 Meltzer HY, Busch DA, Creese IR, Snyder SH, Fang VS. Effect of intramuscular chlorpromazine on serum prolactin levels in schizophrenic patients and normal controls. Psychiatry Research 1981;5:95-105. [DOI: 10.1016/0165-1781(81)90065-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
74 Park SJ, Yang H, Lee SH, Song HS, Park CS, Bae J, Kwon OS, Park TH, Jang J. Dopamine Receptor D1 Agonism and Antagonism Using a Field-Effect Transistor Assay. ACS Nano 2017;11:5950-9. [PMID: 28558184 DOI: 10.1021/acsnano.7b01722] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
75 Stahl SM. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr 2007;12:265-8. [PMID: 17426663 DOI: 10.1017/s1092852900021015] [Cited by in Crossref: 55] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
76 Van Kammen DP, Sternberg DE, Hare TA, Ballenger JC, Marder SR, Post RM, Bunney WE. Schizophrenia: Low spinal fluid GABA levels? Brain Research Bulletin 1980;5:731-5. [DOI: 10.1016/0361-9230(80)90120-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
77 Borroto-Escuela DO, Pintsuk J, Schäfer T, Friedland K, Ferraro L, Tanganelli S, Liu F, Fuxe K. Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia. Ther Adv Psychopharmacol 2016;6:77-94. [PMID: 27141290 DOI: 10.1177/2045125316637570] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
78 Spooren W, Riemer C, Meltzer H. Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 2005;4:967-75. [PMID: 16341062 DOI: 10.1038/nrd1905] [Cited by in Crossref: 95] [Cited by in F6Publishing: 72] [Article Influence: 6.3] [Reference Citation Analysis]
79 Friedman E, Wang H, Butkerait P. Decreased striatal release of acetylcholine following withdrawal from long-term treatment with haloperidol: Modulation by cholinergic, dopamine-D1 and -D2 mechanisms. Neuropharmacology 1990;29:537-44. [DOI: 10.1016/0028-3908(90)90065-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
80 Meltzer HY. Presynaptic Receptors Relevance to Psychotropic Drug Action in Man. Ann NY Acad Sci 1990;604:353-71. [DOI: 10.1111/j.1749-6632.1990.tb32005.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
81 Csernansky JG, Murphy GM, Faustman WO. Limbic/mesolimbic connections and the pathogenesis of schizophrenia. Biol Psychiatry 1991;30:383-400. [PMID: 1912130 DOI: 10.1016/0006-3223(91)90295-w] [Cited by in Crossref: 85] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
82 Rastogi RB, Singhal RL, Lapierre YD. Effects of short- and long-term neuroleptic treatment on brain serotonin synthesis and turnover: Focus on the serotonin hypothesis of schizophrenia. Life Sciences 1981;29:735-41. [DOI: 10.1016/0024-3205(81)90027-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
83 Dewey SL, Macgregor RR, Brodie JD, Bendriem B, King PT, Volkow ND, Schlyer DJ, Fowler JS, Wolf AP, Gatley SJ, Hitzemann R. Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. Synapse 1990;5:213-23. [DOI: 10.1002/syn.890050307] [Cited by in Crossref: 98] [Cited by in F6Publishing: 76] [Article Influence: 3.2] [Reference Citation Analysis]
84 Benrimoh D, Sheldon A, Sibarium E, Powers AR. Computational Mechanism for the Effect of Psychosis Community Treatment: A Conceptual Review From Neurobiology to Social Interaction. Front Psychiatry 2021;12:685390. [PMID: 34385938 DOI: 10.3389/fpsyt.2021.685390] [Reference Citation Analysis]
85 Mash DC, Zabetian CP. Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse 1992;12:195-205. [DOI: 10.1002/syn.890120304] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 1.9] [Reference Citation Analysis]
86 Bogerts B, Falkai P. Clinical and Neurodevelopmental Aspects of Brain Pathology in Schizophrenia. In: Mednick SA, Cannon TD, Barr CE, Lafosse JM, editors. Developmental Neuropathology of Schizophrenia. Boston: Springer US; 1991. pp. 93-120. [DOI: 10.1007/978-1-4615-3378-8_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Thompson PA, Meltzer HY. Positive, Negative, and Disorganisation Factors from the Schedule for Affective Disorders and Schizophrenia and the Present State Examination: A Three-Factor Solution. Br J Psychiatry 1993;163:344-51. [DOI: 10.1192/bjp.163.3.344] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
88 Hodgson NW, Waly MI, Trivedi MS, Power-Charnitsky VA, Deth RC. Methylation-related metabolic effects of D4 dopamine receptor expression and activation. Transl Psychiatry 2019;9:295. [PMID: 31719518 DOI: 10.1038/s41398-019-0630-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
89 Rothman RB, Mele A, Reid AA, Akunne H, Greig N, Thurkauf A, Rice KC, Pert A. Tight binding dopamine reuptake inhibitors as cocaine antagonists: A strategy for drug development. FEBS Letters 1989;257:341-4. [DOI: 10.1016/0014-5793(89)81566-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
90 Guest PC, Martins-de-Souza D, Schwarz E, Rahmoune H, Alsaif M, Tomasik J, Turck CW, Bahn S. Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Med 2013;5:25. [PMID: 23531373 DOI: 10.1186/gm429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
91 Delisi LE, Mirsky AF, Buchsbaum MS, van Kammen DP, Berman KF, Caton C, Kafka MS, Ninan PT, Phelps BH, Karoum F, Ko GN, Korpi ER, Linnoila M, Sheinan M, Wyatt RJ. The Genain quadruplets 25 years later: A diagnostic and biochemical followup. Psychiatry Research 1984;13:59-76. [DOI: 10.1016/0165-1781(84)90119-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
92 Almamy A, Schwerk C, Schroten H, Ishikawa H, Asif AR, Reuss B. Crossreactivity of an Antiserum Directed to the Gram-Negative Bacterium Neisseria gonorrhoeae with the SNARE-Complex Protein Snap23 Correlates to Impaired Exocytosis in SH-SY5Y Cells. J Mol Neurosci 2017;62:163-80. [PMID: 28462458 DOI: 10.1007/s12031-017-0920-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
93 Versteeg DH, Kovács GL, Bohus B, De Kloet ER, De Wied D. Effect of des-tyr1-γ-endorphin and des-tyr1-α-endorphin on α-MPT-induced catecholamine disappearance in rat brain nuclei: A dose-response study. Brain Research 1982;231:343-51. [DOI: 10.1016/0006-8993(82)90371-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
94 Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology 2011;213:289-305. [DOI: 10.1007/s00213-010-2137-8] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 8.6] [Reference Citation Analysis]
95 Csernansky JG, Csernansky CA, Bonnet KA, Hollister LE. Dopaminergic supersensitivity follows ferric chloride-induced limbic seizures. Biological Psychiatry 1985;20:723-33. [DOI: 10.1016/0006-3223(85)90151-9] [Cited by in Crossref: 72] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
96 Csernansky JG, Csernansky CA, Hollister LE. Distinct effects of two stresses on the behavioral response to apomorphine. Life Sciences 1984;35:1513-8. [DOI: 10.1016/0024-3205(84)90169-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
97 Krum BN, Molz de Freitas C, Chiapinotto Ceretta AP, Barbosa CP, de Moraes Reis E, Scussel R, da Silva Córneo E, Machado-de-Ávila RA, Boligon AA, Fachinetto R. Kava decreases the stereotyped behavior induced by amphetamine in mice. J Ethnopharmacol 2021;265:113293. [PMID: 32841698 DOI: 10.1016/j.jep.2020.113293] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Lal S, Nair N, Thavundayil JX, Tawar V, Guyda H, Ayotte C. The effect of methyltestosterone on the growth hormone response to the dopamine receptor agonist, apomorphine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1991;15:263-8. [DOI: 10.1016/0278-5846(91)90090-n] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
99 Payeur R, Nixon M, Bourin M, Bradwejn J, Legrand J. The potential role of cholecystokinin in schizophrenia: review and update. Eur psychiatr 1993;8:67-78. [DOI: 10.1017/s0924933800001358] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Andreou C, Moritz S, Veith K, Veckenstedt R, Naber D. Dopaminergic modulation of probabilistic reasoning and overconfidence in errors: a double-blind study. Schizophr Bull 2014;40:558-65. [PMID: 23661634 DOI: 10.1093/schbul/sbt064] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
101 Nakazawa K, Zsiros V, Jiang Z, Nakao K, Kolata S, Zhang S, Belforte JE. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012;62:1574-83. [PMID: 21277876 DOI: 10.1016/j.neuropharm.2011.01.022] [Cited by in Crossref: 295] [Cited by in F6Publishing: 255] [Article Influence: 29.5] [Reference Citation Analysis]
102 Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 2012;3:195. [PMID: 23189055 DOI: 10.3389/fphar.2012.00195] [Cited by in Crossref: 89] [Cited by in F6Publishing: 73] [Article Influence: 9.9] [Reference Citation Analysis]
103 Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacology & Therapeutics 2003;97:153-79. [DOI: 10.1016/s0163-7258(02)00328-5] [Cited by in Crossref: 224] [Cited by in F6Publishing: 63] [Article Influence: 12.4] [Reference Citation Analysis]
104 Colpaert FC, Niemegeers CJE, Janssen PAJ. Neuroleptic interference with the cocaine cue: Internal stimulus control of behavior and psychosis. Psychopharmacology 1978;58:247-55. [DOI: 10.1007/bf00427387] [Cited by in Crossref: 32] [Article Influence: 0.7] [Reference Citation Analysis]
105 Andreou C, Bozikas VP, Luedtke T, Moritz S. Associations between visual perception accuracy and confidence in a dopaminergic manipulation study. Front Psychol 2015;6:414. [PMID: 25932015 DOI: 10.3389/fpsyg.2015.00414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
106 Rodr�guez J, Garcia D, Nakabeppu Y, Pickel V. FosB in rat striatum: Normal regional distribution and enhanced expression after 6-month haloperidol administration. Synapse 2001;39:122-32. [DOI: 10.1002/1098-2396(200102)39:2<122::aid-syn3>3.0.co;2-r] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
107 Corbin A, Meltzer L, Ninteman F, Wiley J, Christoffersen C, Wustrow D, Wise L, Pugsley T, Heffner T. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT1A agonist actions. II. Preclinical behavioral effects. Neuropharmacology 2000;39:1211-21. [DOI: 10.1016/s0028-3908(99)00214-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Meltzer HY. Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics. In: Gross G, Geyer MA, editors. Current Antipsychotics. Berlin: Springer Berlin Heidelberg; 2012. pp. 87-124. [DOI: 10.1007/978-3-642-25761-2_4] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 7.6] [Reference Citation Analysis]
109 Anderson GD, Rebec GV. Differential response of amygdaloid neurons to clozapine and haloperidol: effects of repeated administration. Pharmacology Biochemistry and Behavior 1986;24:1561-6. [DOI: 10.1016/0091-3057(86)90485-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
110 Weiner I, Joel D. Dopamine in Schizophrenia Dysfunctional Information Processing in Basal Ganglia — Thalamocortical Split Circuits. In: Di Chiara G, editor. Dopamine in the CNS II. Berlin: Springer Berlin Heidelberg; 2002. pp. 417-71. [DOI: 10.1007/978-3-662-06765-9_13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
111 Saia-Cereda VM, Santana AG, Schmitt A, Falkai P, Martins-de-Souza D. The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains. Mol Neuropsychiatry 2017;3:37-52. [PMID: 28879200 DOI: 10.1159/000477299] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
112 Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Natesan S, Turkheimer F, Stone J, Egerton A, McGuire P, Kapur S, Howes OD. The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biol Psychiatry 2019;85:79-87. [PMID: 30122287 DOI: 10.1016/j.biopsych.2018.07.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
113 Chen LC, Bai YM, Chang MH. Polydipsia, hyponatremia and rhabdomyolysis in schizophrenia: A case report. World J Psychiatry 2014;4:150-2. [PMID: 25540730 DOI: 10.5498/wjp.v4.i4.150] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
114 Wachtel H, Kehr W, Sauer G. Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride. Life Sciences 1983;33:2583-97. [DOI: 10.1016/0024-3205(83)90342-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
115 Lehmann J, Langer S. The striatal cholinergic interneuron: Synaptic target of dopaminergic terminals? Neuroscience 1983;10:1105-20. [DOI: 10.1016/0306-4522(83)90102-1] [Cited by in Crossref: 361] [Cited by in F6Publishing: 323] [Article Influence: 9.5] [Reference Citation Analysis]
116 van Kammen DP, Docherty JP, Marder SR, Siris SG, Bunney WE. d-Amphetamine raises serum prolactin in man: Evaluations after chronic placebo, lithium and pimozide treatment. Life Sciences 1978;23:1487-92. [DOI: 10.1016/0024-3205(78)90130-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
117 Ľupták M, Michaličková D, Fišar Z, Kitzlerová E, Hroudová J. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J Psychiatry 2021;11:277-96. [PMID: 34327122 DOI: 10.5498/wjp.v11.i7.277] [Reference Citation Analysis]
118 Ereshefsky L. Treatment Strategies for Schizophrenia. Psychiatric Annals 1995;25:285-96. [DOI: 10.3928/0048-5713-19950501-08] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
119 Minabe Y, Emori K, Toor A, Stutzmann GE, Ashby CR. The effect of the acute and chronic administration of CP 96,345, a selective neurokinin1 receptor antagonist, on midbrain dopamine neurons in the rat: A single unit, extracellular recording study. Synapse 1996;22:35-45. [DOI: 10.1002/(sici)1098-2396(199601)22:1<35::aid-syn4>3.0.co;2-j] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
120 Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 2014;75:292-9. [PMID: 24439555 DOI: 10.1016/j.biopsych.2013.12.002] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 8.6] [Reference Citation Analysis]
121 Galletly C. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology 2009;202:259-73. [DOI: 10.1007/s00213-008-1302-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
122 Domino EF, Mathews BN, Tait SK. Urinary neurotransmitter metabolites in drug-free chronic schizophrenic patients measured by gas chromatography selected positive ion monitoring. Biol Mass Spectrom 1979;6:331-4. [DOI: 10.1002/bms.1200060804] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
123 Hartmann E, Keller-Teschke M. Biology of schizophrenia: Mental effects of dopamine-beta-hydroxylase inhibition in normal men. Lancet 1977;1:37-8. [PMID: 63668 DOI: 10.1016/s0140-6736(77)91668-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Szewczak MR, Cornfeldt ML, Dunn RW, Wilker JC, Geyer HM, Fielding S, Glamkowski EJ, Chiang Y. Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent: 1. In vivo profile. Drug Dev Res 1987;11:157-68. [DOI: 10.1002/ddr.430110303] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
125 Torvinen M, Kalenius E, Sansone F, Casnati A, Jänis J. Noncovalent Complexation of Monoamine Neurotransmitters and Related Ammonium Ions by Tetramethoxy Tetraglucosylcalix[4]arene. J Am Soc Mass Spectrom 2012;23:359-65. [DOI: 10.1007/s13361-011-0289-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
126 Panksepp J. The pleasure in brain substrates of foraging. Behav Brain Sci 1982;5:71-2. [DOI: 10.1017/s0140525x00010566] [Cited by in Crossref: 46] [Article Influence: 4.2] [Reference Citation Analysis]
127 De Luca MA, Lai F, Corrias F, Caboni P, Bimpisidis Z, Maccioni E, Fadda AM, Di Chiara G. Lactoferrin- and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: preparation and in vivo evaluation. Int J Pharm 2015;479:129-37. [PMID: 25560308 DOI: 10.1016/j.ijpharm.2014.12.057] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
128 Vasavan Nair N, Bloom DM, Nestoros JN. Cholecystokinin appears to have antipsychotic properties. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1982;6:509-12. [DOI: 10.1016/s0278-5846(82)80140-1] [Cited by in Crossref: 67] [Article Influence: 1.7] [Reference Citation Analysis]
129 Keks NA, Copolov DL, Kulkarni J, Mackie B, Singh BS, Mcgorry P, Rubin RT, Hassett A, Mclaughlin M, van Riel R. Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. Biological Psychiatry 1990;27:1203-15. [DOI: 10.1016/0006-3223(90)90418-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
130 Fricchione GL, Carbone L, Bennett WI. Psychotic Disorder Caused by a General Medical Condition, with Delusions. Psychiatric Clinics of North America 1995;18:363-78. [DOI: 10.1016/s0193-953x(18)30060-1] [Cited by in Crossref: 19] [Article Influence: 0.7] [Reference Citation Analysis]
131 Van Ree JM, Elands J, Király I, Wolterink G. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems. European Journal of Pharmacology 1989;166:441-52. [DOI: 10.1016/0014-2999(89)90357-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
132 Lundberg T, Lindström L, Hartvig P, Reibring L, Agren H, Lundqvist H, Fasth KJ, Antoni G, Långström B. Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography. Psychiatry Res 1996;67:1-10. [PMID: 8797237 DOI: 10.1016/0925-4927(96)02653-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
133 Angrist B, Rotrosen J, Gershon S. Differential effects of amphetamine and neuroleptics on negative Vs. positive symptoms in schizophrenia. Psychopharmacology 1980;72:17-9. [DOI: 10.1007/bf00433802] [Cited by in Crossref: 249] [Cited by in F6Publishing: 14] [Article Influence: 6.1] [Reference Citation Analysis]
134 Vysokanov A, Flores-hernandez J, Surmeier D. mRNAs for clozapine-sensitive receptors co-localize in rat prefrontal cortex neurons. Neuroscience Letters 1998;258:179-82. [DOI: 10.1016/s0304-3940(98)00882-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
135 Wiegant VM, Ronken E, Kovács G, De Wied D. Chapter 29 Endorphins and schizophrenia. The Human Hypothalamus in Health and Disease, Proceedings of the 17th International Summer School of Brain Research, held at the Auditorium of the University of Amsterdam. Elsevier; 1992. pp. 433-53. [DOI: 10.1016/s0079-6123(08)64588-4] [Cited by in Crossref: 17] [Article Influence: 0.6] [Reference Citation Analysis]
136 Megens AA, Kennis LE. 5 Risperidone and related 5HT2/D2 antagonists: A new type of antipsychotic agent? Elsevier; 1996. pp. 185-232. [DOI: 10.1016/s0079-6468(08)70306-0] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
137 Ichikawa J, Meltzer HY. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 2000;858:252-63. [PMID: 10708676 DOI: 10.1016/s0006-8993(99)02346-x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
138 du Verglas G, Banks SR, Guyer KE. Clinical effects of fenfluramine on children with autism: A review of the research. J Autism Dev Disord 1988;18:297-308. [DOI: 10.1007/bf02211954] [Cited by in Crossref: 27] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
139 Levant B, Ozias MK, Carlson SE. Sex-specific effects of brain LC-PUFA composition on locomotor activity in rats. Physiology & Behavior 2006;89:196-204. [DOI: 10.1016/j.physbeh.2006.06.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
140 Meltzer HY, Bastani B, Ramirez L, Matsubara S. Clozapine: New research on efficacy and mechanism of action. Eur Arch Psychiatr Neurol Sci 1989;238:332-9. [DOI: 10.1007/bf00449814] [Cited by in Crossref: 71] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
141 Wolf R, Paelchen K, Matzke K, Dobrowolny H, Bogerts B, Schwegler H. Acute or subchronic clozapine treatment does not ameliorate prepulse inhibition (PPI) deficits in CPB-K mice with low levels of hippocampal NMDA receptor density. Psychopharmacology 2007;194:93-102. [DOI: 10.1007/s00213-007-0824-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
142 Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, Surmeier DJ. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci 2000;20:8987-95. [PMID: 11124974 [PMID: 11124974 DOI: 10.1523/jneurosci.20-24-08987.2000] [Cited by in Crossref: 339] [Article Influence: 17.0] [Reference Citation Analysis]
143 Dewry SL, Brodie JD, Fowler JS, Macgregor RR, Schlyer DJ, King PT, Alexoff DL, Volkow ND, Shiue C, Wolf AP, Bendriem B. Positron emission tomography (PET) studies of dopaminergic/cholinergic interaction in the baboon brain. Synapse 1990;6:321-7. [DOI: 10.1002/syn.890060403] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 1.3] [Reference Citation Analysis]
144 Piazza P, Calzà L, Giardino L, Amato G. Chronic thioridazine treatment differently affects DA receptors in striatum and in mesolimbo-cortical systems. Pharmacology Biochemistry and Behavior 1990;35:937-42. [DOI: 10.1016/0091-3057(90)90382-r] [Cited by in Crossref: 7] [Article Influence: 0.2] [Reference Citation Analysis]
145 Essig EC, Kilpatrick IC. Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala. Psychopharmacology 1991;104:194-200. [DOI: 10.1007/bf02244178] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
146 Nestoros JN, Lehmann HE, Ban TA. Sexual behavior of the male schizophrenic: the impact of illness and medications. Arch Sex Behav 1981;10:421-42. [PMID: 6119066 DOI: 10.1007/BF01541435] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
147 Bunney B, Grace A. Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sciences 1978;23:1715-27. [DOI: 10.1016/0024-3205(78)90471-x] [Cited by in Crossref: 435] [Cited by in F6Publishing: 52] [Article Influence: 10.1] [Reference Citation Analysis]
148 Healy D. Neuroleptics and Psychic Indifference: A Review. J R Soc Med 1989;82:615-9. [DOI: 10.1177/014107688908201018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
149 Meltzer HY. Multireceptor atypical antipsychotic drugs. In: Ellenbroek BA, Cools AR, editors. Atypical Antipsychotics. Basel: Birkhäuser; 2000. pp. 191-213. [DOI: 10.1007/978-3-0348-8448-8_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
150 Ree JM, Verhoeven WMA, Wied D, Praag HM. THE USE OF THE SYNTHETIC PEPTIDES ?-TYPE ENDORPHINS IN MENTALLY ILL PATIENTS. Ann NY Acad Sci 1982;398:478-95. [DOI: 10.1111/j.1749-6632.1982.tb39519.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
151 Meltzer HY, Fessler RG, Simonovic M, Doherty J, Fang VS. Effect of d- and l-amphetamine on rat plasma prolactin levels. Psychopharmacology (Berl) 1979;61:63-9. [PMID: 108721 DOI: 10.1007/BF00426812] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
152 Claridge G. LSD: A missed opportunity? Hum Psychopharmacol Clin Exp 1994;9:343-51. [DOI: 10.1002/hup.470090504] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
153 Grace AA, Bunney BS. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--1. Identification and characterization. Neuroscience 1983;10:301-15. [PMID: 6633863 DOI: 10.1016/0306-4522(83)90135-5] [Cited by in Crossref: 648] [Cited by in F6Publishing: 643] [Article Influence: 17.1] [Reference Citation Analysis]
154 Freed WJ, Hoffer BJ, Olson L, Wyatt RJ. Transplantation of Catecholamine-Containing Tissues to Restore the Functional Capacity of the Damaged Nigrostriatal System. In: Sladek JR, Gash DM, editors. Neural Transplants. Boston: Springer US; 1984. pp. 373-406. [DOI: 10.1007/978-1-4684-4685-2_16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
155 De Jesus OT, Friedman AM. Radiobrominated spiroperidol for the study of dopamine D2 receptors. International Journal of Radiation Applications and Instrumentation Part A Applied Radiation and Isotopes 1986;37:719-26. [DOI: 10.1016/0883-2889(86)90266-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
156 Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33:1120-30. [PMID: 17641146 DOI: 10.1093/schbul/sbm083] [Cited by in Crossref: 133] [Cited by in F6Publishing: 117] [Article Influence: 9.5] [Reference Citation Analysis]
157 Alpert M, Diamond F, Weisenfreund J, Taleporos E, Friedhoff AJ. The Neuroleptic Hypothesis: Study of the Covariation of Extrapyramidal and Therapeutic Drug Effects. Br J Psychiatry 1978;133:169-75. [DOI: 10.1192/bjp.133.2.169] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
158 Krieger NR, Bunney BS, Greengard P. Localization of dopamine-sensitive adenylate cyclase activity within laminae of the rat prefrontal cortex. Brain Research 1979;179:171-5. [DOI: 10.1016/0006-8993(79)90502-x] [Cited by in Crossref: 7] [Article Influence: 0.2] [Reference Citation Analysis]
159 Anderson JR. More on rational analysis. Behav Brain Sci 1991;14:508-17. [DOI: 10.1017/s0140525x00071077] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
160 Ribeyre JM, Lesieur P, Varoquaux O, Dollfus S, Pays M, Petit M. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 1994;36:230-6. [PMID: 7986887 DOI: 10.1016/0006-3223(94)90604-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]
161 Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018;23:187-191. [PMID: 29954475 DOI: 10.1017/s1092852918001013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
162 Procyshyn RM, Kennedy NB. Theoretical Basis for Loxapine Augmentation in Risperidone Partial Responders: . Clinical Drug Investigation 2000;19:257-66. [DOI: 10.2165/00044011-200019040-00003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
163 Alcaro A, Huber R, Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev. 2007;56:283-321. [PMID: 17905440 DOI: 10.1016/j.brainresrev.2007.07.014] [Cited by in Crossref: 261] [Cited by in F6Publishing: 174] [Article Influence: 18.6] [Reference Citation Analysis]
164 Ögren SO. The Behavioural Pharmacology of Typical and Atypical Antipsychotic Drugs. In: Csernansky JG, editor. Antipsychotics. Berlin: Springer Berlin Heidelberg; 1996. pp. 225-66. [DOI: 10.1007/978-3-642-61007-3_8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
165 Tatara A, Shimizu S, Shin N, Sato M, Sugiuchi T, Imaki J, Ohno Y. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:252-9. [PMID: 22542492 DOI: 10.1016/j.pnpbp.2012.04.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
166 Oakley NR, Hayes AG, Sheehan MJ. Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat. Psychopharmacology 1991;105:204-8. [DOI: 10.1007/bf02244310] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
167 Carlson KM, Wagner GC. Effects of phencyclidine on schedule-controlled responding following neurotoxic lesions of the striatum. Life Sciences 2005;77:372-85. [DOI: 10.1016/j.lfs.2004.08.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
168 Dethloff LA, De La Iglesia FA. Cholecystokinin Antagonists—A Toxicologic Perspective. Drug Metabolism Reviews 2008;24:267-93. [DOI: 10.3109/03602539208996295] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
169 Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) 2003;169:257-97. [PMID: 12601500 DOI: 10.1007/s00213-002-1313-x] [Cited by in Crossref: 290] [Cited by in F6Publishing: 236] [Article Influence: 16.1] [Reference Citation Analysis]
170 M�ller-spahn F, Ackenheil M, Albus M, May G, Naber D, Welter D, Zander K. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: Relations to psychopathology and tardive dyskinesia. Psychopharmacology 1984;84:436-40. [DOI: 10.1007/bf00555228] [Cited by in Crossref: 16] [Article Influence: 0.4] [Reference Citation Analysis]
171 Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. Biochem Biophys Res Commun. 2014;443:278-284. [PMID: 24309097 DOI: 10.1016/j.bbrc.2013.11.104] [Cited by in Crossref: 55] [Cited by in F6Publishing: 33] [Article Influence: 6.9] [Reference Citation Analysis]
172 Torres-hernández AR, González-vegas JA. Effects of 17β-estradiol on the spontaneous activity of substantia nigra neurons: Evidence for a non-genomic mechanism. Brain Research 2005;1049:1-7. [DOI: 10.1016/j.brainres.2005.04.085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
173 Katz RJ. Dopamine and the limits of behavioral reduction – or why aren't all schizophrenics fat and happy? Behav Brain Sci 1982;5:60-1. [DOI: 10.1017/s0140525x00010451] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
174 Karbe H, Wienhard K, Hamacher K, Huber M, Herholz K, Coenen HH, Stöcklin G, Lövenich A, Heiss WD. Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm Gen Sect 1991;86:163-73. [PMID: 1837996 DOI: 10.1007/BF01250702] [Cited by in Crossref: 30] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
175 Maas JW, Contreras SA, Bowden CL, Weintraub SE. Effects of debrisoquin on CSF and plasma HVA concentrations in man. Life Sci 1985;36:2163-70. [PMID: 3999921 DOI: 10.1016/0024-3205(85)90313-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 0.8] [Reference Citation Analysis]
176 Sarnyai Z, Alsaif M, Bahn S, Ernst A, Guest PC, Hradetzky E, Kluge W, Stelzhammer V, Wesseling H. Behavioral and molecular biomarkers in translational animal models for neuropsychiatric disorders. Int Rev Neurobiol 2011;101:203-38. [PMID: 22050853 DOI: 10.1016/B978-0-12-387718-5.00008-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
177 Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Research Reviews 1999;29:250-64. [DOI: 10.1016/s0165-0173(99)00002-8] [Cited by in Crossref: 124] [Cited by in F6Publishing: 15] [Article Influence: 5.6] [Reference Citation Analysis]
178 Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 2007;51:s13-8. [PMID: 18055930 DOI: 10.1192/bjp.191.51.s13] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 6.2] [Reference Citation Analysis]
179 Baldessarini RJ, Huston-lyons D, Campbell A, Marsh E, Cohen BM. Do Central Antiadrenergic Actions Contribute to the Atypical Properties of Clozapine? Br J Psychiatry 1992;160:12-6. [DOI: 10.1192/s0007125000296852] [Cited by in Crossref: 73] [Article Influence: 24.3] [Reference Citation Analysis]
180 Nullmeier S, Panther P, Dobrowolny H, Frotscher M, Zhao S, Schwegler H, Wolf R. Region-specific alteration of GABAergic markers in the brain of heterozygous reeler mice. Eur J Neurosci 2011;33:689-98. [PMID: 21226776 DOI: 10.1111/j.1460-9568.2010.07563.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
181 Meltzer H. Multiple neurotransmitters involved in antipsychotic drug action. In: Kapur S, Lecrubier Y, editors. Dopamine in the Pathophysiology and Treatment of Schizophrenia. CRC Press; 2003. pp. 177-205. [DOI: 10.3109/9780203427347-10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
182 Lewine RJ, Meltzer HY. Negative symptoms and platelet monoamine oxidase activity in male schizophrenic patients. Psychiatry Res. 1984;12:99-109. [PMID: 6591224 DOI: 10.1016/0165-1781(84)90010-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 0.7] [Reference Citation Analysis]
183 Bannon MJ, Freeman AS, Chiodo LA, Bunney BS, Roth RH. The Electrophysiological and Biochemical Pharmacology of the Mesolimbic and Mesocortical Dopamine Neurons. In: Iversen LL, Iversen SD, Snyder SH, editors. Handbook of Psychopharmacology. Boston: Springer US; 1987. pp. 329-74. [DOI: 10.1007/978-1-4613-1819-4_5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
184 Davis KL, Fiori M, Davis BM, Mohs RC, Horvath TB, Davidson M. Dopaminergic dysregulation in schizophrenia: A target for new drugs. Drug Dev Res 1986;9:71-83. [DOI: 10.1002/ddr.430090109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
185 Weiner I, Gaisler I, Schiller D, Green A, Zuckerman L, Joel D. Screening of antipsychotic drugs in animal models. Drug Dev Res 2000;50:235-49. [DOI: 10.1002/1098-2299(200007/08)50:3/4<235::aid-ddr7>3.0.co;2-r] [Cited by in Crossref: 15] [Article Influence: 0.7] [Reference Citation Analysis]
186 Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24. [PMID: 17242588 DOI: 10.1097/00131746-200701000-00003] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 5.9] [Reference Citation Analysis]
187 Meltzer HY. Clozapine: Mechanism of Action in Relation to its Clinical Advantages. Recent Advances in Schizophrenia. New York: Springer; 1990. pp. 237-56. [DOI: 10.1007/978-1-4612-3248-3_11] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
188 Schlemmer RF, Young JE, Davis JM. Stimulant-induced disruption of non-human primate social behavior and the psychopharmacology of schizophrenia. J Psychopharmacol 1996;10:64-76. [DOI: 10.1177/026988119601000110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
189 Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP. Striatal binding of the PET ligand11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993;13:350-6. [DOI: 10.1002/syn.890130407] [Cited by in Crossref: 205] [Cited by in F6Publishing: 186] [Article Influence: 7.3] [Reference Citation Analysis]
190 Chastain LG, Qu H, Bourke CH, Iuvone PM, Dobner PR, Nemeroff CB, Kinkead B. Striatal dopamine receptor plasticity in neurotensin deficient mice. Behav Brain Res 2015;280:160-71. [PMID: 25449842 DOI: 10.1016/j.bbr.2014.11.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
191 van Kammen DP. The dopamine hypothesis of schizophrenia revisited. Psychoneuroendocrinology 1979;4:37-46. [DOI: 10.1016/0306-4530(79)90039-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 1.1] [Reference Citation Analysis]
192 Reuss B, Schroten H, Ishikawa H, Asif AR. Cross-reactivity of Antibodies Directed to the Gram-Negative Bacterium Neisseria gonorrhoeae With Heat Shock Protein 60 and ATP-Binding Protein Correlates to Reduced Mitochondrial Activity in HIBCPP Choroid Plexus Papilloma Cells. J Mol Neurosci 2015;57:123-38. [PMID: 26080747 DOI: 10.1007/s12031-015-0585-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
193 Delisi LE, Wise C, Bridge T, Rosenblatt JE, Wagner RL, Morihisa J, Karson C, Potkin SG, Wyatt RJ. A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. Psychiatry Research 1981;4:95-107. [DOI: 10.1016/0165-1781(81)90013-5] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 2.0] [Reference Citation Analysis]
194 Bardgett ME, Wrona CT, Newcomer JW, Csernansky JG. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. European Journal of Pharmacology 1993;230:245-50. [DOI: 10.1016/0014-2999(93)90557-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
195 Barnes JM, Barnes NM, Cooper SJ. Behavioural pharmacology of 5-HT3 receptor ligands. Neuroscience & Biobehavioral Reviews 1992;16:107-13. [DOI: 10.1016/s0149-7634(05)80057-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
196 Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol 2007;21:620-7. [PMID: 17092971 DOI: 10.1177/0269881106072090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
197 Tyler MW, Yourish HB, Ionescu DF, Haggarty SJ. Classics in Chemical Neuroscience: Ketamine. ACS Chem Neurosci 2017;8:1122-34. [DOI: 10.1021/acschemneuro.7b00074] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 12.8] [Reference Citation Analysis]
198 Kendler KS. Levels of explanation in psychiatric and substance use disorders: implications for the development of an etiologically based nosology. Mol Psychiatry 2012;17:11-21. [PMID: 21670729 DOI: 10.1038/mp.2011.70] [Cited by in Crossref: 66] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
199 Dean B, Bradbury R, Copolov DL. Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. Biological Psychiatry 2003;53:585-92. [DOI: 10.1016/s0006-3223(02)01545-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
200 Dahoun T, Nour MM, McCutcheon RA, Adams RA, Bloomfield MAP, Howes OD. The relationship between childhood trauma, dopamine release and dexamphetamine-induced positive psychotic symptoms: a [11C]-(+)-PHNO PET study. Transl Psychiatry 2019;9:287. [PMID: 31712556 DOI: 10.1038/s41398-019-0627-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
201 Möller M, Swanepoel T, Harvey BH. Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development. ACS Chem Neurosci 2015;6:987-1016. [DOI: 10.1021/cn5003368] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
202 Russell RL, Pihl RO. Determinants of Amphetamine-Produced Stereotyped Behavior in the Rat. Psychol Rep 1978;43:575-9. [DOI: 10.2466/pr0.1978.43.2.575] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
203 Buccafusco JJ. Kinetics of [3H]choline and [3H]acetylcholine metabolism in several regions of rat brain following intracerebroventricular injection of [3H]choline. Biochemical Pharmacology 1982;31:1599-605. [DOI: 10.1016/0006-2952(82)90387-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
204 Koob GF. The dopamine anhedonia hypothesis: A pharmacological phrenology. Behav Brain Sci 1982;5:63-4. [DOI: 10.1017/s0140525x00010475] [Cited by in Crossref: 23] [Article Influence: 2.1] [Reference Citation Analysis]
205 Angelopoulos EK, Markianos M, Daskalopoulou EG, Hatzimanolis J, Tzemos J. Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia. Psychiatry Res 2002;110:9-17. [PMID: 12007589 DOI: 10.1016/s0165-1781(02)00037-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
206 Dichter GS, Damiano CA, Allen JA. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. J Neurodev Disord 2012;4:19. [PMID: 22958744 DOI: 10.1186/1866-1955-4-19] [Cited by in Crossref: 149] [Cited by in F6Publishing: 124] [Article Influence: 16.6] [Reference Citation Analysis]
207 Nasrallah HA. The unintegrated right cerebral hemispheric consciousness as alien intruder: A possible mechanism for schneiderian delusions in schizophrenia. Comprehensive Psychiatry 1985;26:273-82. [DOI: 10.1016/0010-440x(85)90072-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
208 Nerozzi D, Magnani A, Sforza V, Scaramucci E, Cerilli M, Moretti C, Frajese G, Antonozzi I, Meltzer HY. Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness. Psychiatry Research 1990;34:139-47. [DOI: 10.1016/0165-1781(90)90015-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
209 Den Boer JA, Vahlne J, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Hum Psychopharmacol Clin Exp 2000;15:179-89. [DOI: 10.1002/(sici)1099-1077(200004)15:3<179::aid-hup156>3.0.co;2-n] [Cited by in Crossref: 31] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
210 Barak S, Weiner I. The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. International Journal of Neuropsychopharmacology 2011;14:1233-46. [DOI: 10.1017/s1461145710001549] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
211 Joseph MH, Frith CD, Waddington JL. Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model. Psychopharmacology (Berl) 1979;63:273-80. [PMID: 113814 DOI: 10.1007/BF00433561] [Cited by in Crossref: 81] [Cited by in F6Publishing: 2] [Article Influence: 1.9] [Reference Citation Analysis]
212 Meltzer HY. Serotonin receptors and antipsychotic drug action. Psychopharmacol Ser 1993;10:70-81. [PMID: 8103227 DOI: 10.1007/978-3-642-78010-3_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.0] [Reference Citation Analysis]
213 Kirch DG, Jaskiw G, Linnoila M, Weinberger DR, Wyatt RJ. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients. Psychiatry Research 1988;25:233-42. [DOI: 10.1016/0165-1781(88)90094-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
214 Ginsburg BE, Werick TM, Escobar JI, Kugelmass S, Treanor JJ, Wendtland L. Molecular genetics of psychopathologies: A search for simple answers to complex problems. Behav Genet 1996;26:325-33. [DOI: 10.1007/bf02359388] [Cited by in Crossref: 31] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
215 Sloviter R, J.d. C, Drust E. Serotonergic properties of β-phenethylamine in rats. Neuropharmacology 1980;19:1071-4. [DOI: 10.1016/0028-3908(80)90103-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 1.2] [Reference Citation Analysis]
216 Tsou JY. Intervention, causal reasoning, and the neurobiology of mental disorders: Pharmacological drugs as experimental instruments. Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 2012;43:542-51. [DOI: 10.1016/j.shpsc.2012.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
217 Miller R. Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: Practical and theoretical implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1997;21:1059-94. [DOI: 10.1016/s0278-5846(97)00099-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
218 Lowe JA, Seeger TF, Vinick FJ. Atypical antipsychotics—recent findings and new perspectives. Med Res Rev 1988;8:475-97. [DOI: 10.1002/med.2610080403] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
219 Ding Y, Logan J, Bermel R, Garza V, Rice O, Fowler JS, Volkow ND. Dopamine Receptor-Mediated Regulation of Striatal Cholinergic Activity: Positron Emission Tomography Studies with Norchloro[18F]fluoroepibatidine. Journal of Neurochemistry 2000;74:1514-21. [DOI: 10.1046/j.1471-4159.2000.0741514.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
220 Tuckwell HC, Koziol JA. On the concentration of 5-hydroxyindoleacetic acid in schizophrenia: a meta-analysis. Psychiatry Res 1996;59:239-44. [PMID: 8930029 DOI: 10.1016/0165-1781(95)02741-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
221 Wright JL, Gregory TF, Heffner TG, Mackenzie RG, Pugsley TA, Meulen SV, Wise LD. Discovery of selective dopamine D4 receptor antagonists: 1-Aryloxy-3-(4-aryloxypiperidinyl)-2-propanols. Bioorganic & Medicinal Chemistry Letters 1997;7:1377-80. [DOI: 10.1016/s0960-894x(97)00233-3] [Cited by in Crossref: 29] [Article Influence: 1.2] [Reference Citation Analysis]
222 Klaus K, Pennington K. Dopamine and Working Memory: Genetic Variation, Stress and Implications for Mental Health. In: Hodgson T, editor. Processes of Visuospatial Attention and Working Memory. Cham: Springer International Publishing; 2019. pp. 369-91. [DOI: 10.1007/7854_2019_113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
223 Lacroix LP, Hows MEP, Shah AJ, Hagan JJ, Heidbreder CA. Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex. Neuropsychopharmacol 2003;28:839-49. [DOI: 10.1038/sj.npp.1300114] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 3.6] [Reference Citation Analysis]
224 Staton DM, Solomon PR. Microinjections of d-amphetamine into the nucleus accumbens and caudate-putamen differentially affect stereotypy and locomotion in the rat. Psychobiology 1984;12:159-62. [DOI: 10.3758/bf03332184] [Cited by in Crossref: 122] [Article Influence: 15.3] [Reference Citation Analysis]
225 Hamelin BA, Dorson PG, Pabis D, Still D, Bouchard RH, Pourcher E, Rail J, Turgeon J, Crismon ML. CYP2D6 mutations and therapeutic outcome in schizophrenic patients. Pharmacotherapy 1999;19:1057-63. [PMID: 10610012 DOI: 10.1592/phco.19.13.1057.31593] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
226 Meyer F, Louilot A. Consequences at adulthood of transient inactivation of the parahippocampal and prefrontal regions during early development: new insights from a disconnection animal model for schizophrenia. Front Behav Neurosci 2014;8:118. [PMID: 24778609 DOI: 10.3389/fnbeh.2014.00118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
227 Andrade YCP, Ropke J, Viana TG, Fanelli C, Minaldi E, Batista LA, Issy AC, Del Bel EA, Rodrigues LCM, Liégeois JF, Moreira FA. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity. Behav Pharmacol 2021;32:2-8. [PMID: 33399294 DOI: 10.1097/FBP.0000000000000595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Chen EY. A Neural Network Model of Cortical Information Processing in Schizophrenia. I: Interaction between Biological and Social Factors in Symptom Formation. Can J Psychiatry 1994;39:362-7. [DOI: 10.1177/070674379403900803] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
229 Nullmeier S, Elmers C, D'Hanis W, Sandhu KVK, Stork O, Yanagawa Y, Panther P, Schwegler H. Glutamic acid decarboxylase 67 haplodeficiency in mice: consequences of postweaning social isolation on behavior and changes in brain neurochemical systems. Brain Struct Funct 2020;225:1719-42. [PMID: 32514634 DOI: 10.1007/s00429-020-02087-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
230 Zhang X, Sun B, Jin G. Atypical neuroleptic properties ofl-stepholidine: Electrophysiological and behavioral studies. Sci China Ser C -Life Sci 1997;40:531-8. [DOI: 10.1007/bf03183593] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
231 Cohen SM, Tsien RW, Goff DC, Halassa MM. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res. 2015;Jan 9; Epub ahead of print. [PMID: 25583246 DOI: 10.1016/j.schres.2014.12.026] [Cited by in Crossref: 125] [Cited by in F6Publishing: 92] [Article Influence: 20.8] [Reference Citation Analysis]
232 Anderson JR. Is human cognition adaptive? Behav Brain Sci 1991;14:471-85. [DOI: 10.1017/s0140525x00070801] [Cited by in Crossref: 176] [Article Influence: 17.6] [Reference Citation Analysis]
233 Shepard PD, Mihailoff GA, German DC. Anatomical and electrophysiological characterization of presumed dopamine-containing neurons within the supramammillary region of the rat. Brain Research Bulletin 1988;20:307-14. [DOI: 10.1016/0361-9230(88)90060-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
234 David Sturgeon R, Fessler RG, Meltzer HY. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotypes behavior and ataxia in rats. European Journal of Pharmacology 1979;59:169-79. [DOI: 10.1016/0014-2999(79)90279-6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 173] [Article Influence: 4.5] [Reference Citation Analysis]
235 Cochran S, Mckerchar C, Morris B, Pratt J. Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol. Neuropharmacology 2002;43:394-407. [DOI: 10.1016/s0028-3908(02)00091-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
236 Moncrieff J. A critique of the dopamine hypothesis of schizophrenia and psychosis. Harv Rev Psychiatry. 2009;17:214-225. [PMID: 19499420 DOI: 10.1080/10673220902979896] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
237 Rolland B, Amad A, Poulet E, Bordet R, Vignaud A, Bation R, Delmaire C, Thomas P, Cottencin O, Jardri R. Resting-state functional connectivity of the nucleus accumbens in auditory and visual hallucinations in schizophrenia.Schizophr Bull. 2015;41:291-299. [PMID: 25053649 DOI: 10.1093/schbul/sbu097] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 8.4] [Reference Citation Analysis]
238 Ridley R, Baker H, Owen F, Cross A, Crow T. Behavioural and biochemical effects of chronic treatment with amphetamine in the vervet monkey. Neuropharmacology 1983;22:551-4. [DOI: 10.1016/0028-3908(83)90178-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
239 Benvenga MJ, Leander JD. Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology 1995;119:133-8. [DOI: 10.1007/bf02246153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
240 Moss D, Koob G, Mcmaster S, Janowsky D. Comparative effects of tetrahydrocannabinol on psychostimulant-induced behaviors. Pharmacology Biochemistry and Behavior 1984;21:641-4. [DOI: 10.1016/s0091-3057(84)80050-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
241 Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest 2013;123:4986-91. [PMID: 24292660 DOI: 10.1172/JCI70678] [Cited by in Crossref: 74] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
242 Meltzer HY, Ying Zhang, Stockmeier CA. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: Implications for antipsychotic action. European Journal of Pharmacology 1992;216:67-71. [DOI: 10.1016/0014-2999(92)90210-u] [Cited by in Crossref: 27] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
243 Ereshefsky L, Richards AL. Psychoses. In: Koda-kimble MA, Young LY, editors. Applied Therapeutics. London: Palgrave Macmillan UK; 1992. pp. 1065-107. [DOI: 10.1007/978-1-349-13175-4_56] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
244 Bacil RP, de O. Marcondes Filho EA, de A. Dias K, Portes MC, de Araujo WR, Oliveira-silva D, dos Santos AA, Serrano SH. The chemical interaction between the neurotransmitter dopamine and the antipsychotic drugs olanzapine and quetiapine. Journal of Electroanalytical Chemistry 2021;881:114946. [DOI: 10.1016/j.jelechem.2020.114946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
245 Metz J, Goode DJ, Meltzer HY. Descriptive studies of H-reflex recovery curves in psychiatric patients. Psychol Med 1980;10:541-8. [PMID: 6108587 DOI: 10.1017/s0033291700047437] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
246 Meltzer HY, Busch D, Fang VS. Hormones, dopamine receptors and schizophrenia. Psychoneuroendocrinology 1981;6:17-36. [DOI: 10.1016/0306-4530(81)90045-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
247 Tueting P, Kaskey G, Buchsbaum M, Connolly J, Perris C, Roemer R. ERPs and psychopathology. II. Biological issues. Ann N Y Acad Sci 1984;425:523-45. [PMID: 6146279 DOI: 10.1111/j.1749-6632.1984.tb23574.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
248 Rosenfeld MR, Seeger TF, Sharpless NS, Gardner EL, Makman MH. Denervation supersensitivity in the mesolimbic system: involvement of dopamine-stimulated adenylate cyclase. Brain Research 1979;173:572-6. [DOI: 10.1016/0006-8993(79)90255-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.4] [Reference Citation Analysis]
249 Shimizu S, Sogabe S, Yanagisako R, Inada A, Yamanaka M, Iha HA, Ohno Y. Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway. Int J Mol Sci 2017;18:E1416. [PMID: 28671605 DOI: 10.3390/ijms18071416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
250 Yasushi M, Itsuko U, Kensuke H, Kohji N, Michio Y. Effects of ceruletide on clinical symptoms and eegs in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1988;12:511-22. [DOI: 10.1016/0278-5846(88)90110-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
251 Moroji T, Itoh K, Itoh K. Antipsychotic Effects of Ceruletide in Chronic Schizophrenia: An Appraisal of the Long-term, Intermittent Medication of Ceruletide in Chronic Schizophrenia. Annals of the New York Academy of Sciences 1985;448:518-34. [DOI: 10.1111/j.1749-6632.1985.tb29945.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
252 de Wied D. Schizophrenia as an inborn error in the degradation of β-endorphin — a hypothesis. Trends in Neurosciences 1979;2:79-82. [DOI: 10.1016/0166-2236(79)90033-x] [Cited by in Crossref: 42] [Article Influence: 1.0] [Reference Citation Analysis]
253 Hibino H, Tochigi M, Otowa T, Kato N, Sasaki T. No association of DRD2, DRD3, and tyrosine hydroxylase gene polymorphisms with personality traits in the Japanese population. Behav Brain Funct 2006;2:32. [PMID: 17018139 DOI: 10.1186/1744-9081-2-32] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
254 Kilts CD, Anderson CM, Bissette G, Ely TD, Nemeroff CB. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochemical Pharmacology 1988;37:1547-54. [DOI: 10.1016/0006-2952(88)90017-2] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 2.5] [Reference Citation Analysis]
255 Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors : their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003;27:1159-72. [DOI: 10.1016/j.pnpbp.2003.09.010] [Cited by in Crossref: 554] [Cited by in F6Publishing: 473] [Article Influence: 30.8] [Reference Citation Analysis]
256 Nair N, Lal S, Bloom DM. Cholecystokinin peptides, dopamine and schizophrenia — A review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1985;9:515-24. [DOI: 10.1016/0278-5846(85)90011-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 1.1] [Reference Citation Analysis]
257 Dourish C. Behavioural effects of acute and chronic β-phenylethylamine administration in the rat: Evidence for the involvement of 5-hydroxytryptamine. Neuropharmacology 1981;20:1067-72. [DOI: 10.1016/0028-3908(81)90098-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 1.2] [Reference Citation Analysis]
258 Figueira FH, Leal CQ, de Moraes Reis E, Röpke J, Wagner C, da Rocha JBT, Fachinetto R. Effects of diphenyl diselenide on behavioral and biochemical changes induced by amphetamine in mice. J Neural Transm 2015;122:201-9. [DOI: 10.1007/s00702-014-1257-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
259 Bujas-Bobanovic M, Bird DC, Robertson HA, Dursun SM. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol 2000;130:1005-12. [PMID: 10882384 DOI: 10.1038/sj.bjp.0703406] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 2.9] [Reference Citation Analysis]
260 Csernansky JG. Treatment of schizophrenia: preventing the progression of disease. Psychiatric Clinics of North America 2003;26:367-79. [DOI: 10.1016/s0193-953x(02)00113-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
261 Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schxzophrenia. Acta Psychiatr Scand 1994;90:95-101. [DOI: 10.1111/j.1600-0447.1994.tb05897.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
262 Schlemmer R, Davis J. SIMILARITIES IN THE BEHAVIORAL EFFECTS OF d-AMPHETAMINE AND APOMORPHINE IN SELECTED MEMBERS OF A PRIMATE SOCIAL COLONY. Recent Advances in Neuropsycho-Pharmacology. Elsevier; 1981. pp. 3-12. [DOI: 10.1016/b978-0-08-026382-3.50005-0] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
263 Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. Journal of Psychiatric Research 1985;19:57-64. [DOI: 10.1016/0022-3956(85)90068-8] [Cited by in Crossref: 167] [Cited by in F6Publishing: 128] [Article Influence: 4.6] [Reference Citation Analysis]
264 Castelão J, Ferreira L, Gelders YG, Heylen SL. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis. Schizophrenia Research 1989;2:411-5. [DOI: 10.1016/0920-9964(89)90034-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 50] [Article Influence: 2.1] [Reference Citation Analysis]
265 McCullumsmith RE, Hammond J, Funk A, Meador-Woodruff JH. Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia. Curr Pharm Biotechnol 2012;13:1535-42. [PMID: 22283761 DOI: 10.2174/138920112800784899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
266 Piekar D. Neuroleptics, Dopamine, and Schizophrenia. Psychiatric Clinics of North America 1986;9:35-48. [DOI: 10.1016/s0193-953x(18)30633-6] [Cited by in Crossref: 13] [Article Influence: 0.4] [Reference Citation Analysis]
267 De Jesus OT, Van Hoffaert GJ, Glock D, Goldber LI, Friedman AH. Synthesis of a radiobrominated analog of SCH 23390, a selfctive dopamine D1/DA1 antagonist. J Label Compd Radiopharm 1986;23:919-25. [DOI: 10.1002/jlcr.2580230902] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
268 Varoqui H, Erickson JD. Vesicular neurotransmitter transporters: Potential sites for the regulation of synaptic function. Mol Neurobiol 1997;15:165-91. [DOI: 10.1007/bf02740633] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
269 Siever LJ, van Kammen DP, Linnoila M, Alterman I, Hare T, Murphy DL. Smooth pursuit eye movement disorder and its psychobiologic correlates in unmedicated schizophrenics. Biological Psychiatry 1986;21:1167-74. [DOI: 10.1016/0006-3223(86)90223-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 0.8] [Reference Citation Analysis]
270 Gray N, Pickering A, Gray J, Jones S, Abrahams S, Hemsley D. Kamin blocking is not disrupted by amphetamine in human subjects. J Psychopharmacol 1997;11:301-11. [DOI: 10.1177/026988119701100404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
271 Quednow BB, Geyer MA, Halberstadt AL. Serotonin and Schizophrenia. Handbook of the Behavioral Neurobiology of Serotonin. Elsevier; 2010. pp. 585-620. [DOI: 10.1016/s1569-7339(10)70102-8] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
272 Seeman MV. History of the dopamine hypothesis of antipsychotic action. World J Psychiatry 2021;11:355-64. [PMID: 34327128 DOI: 10.5498/wjp.v11.i7.355] [Reference Citation Analysis]
273 Devoto P, Sagheddu C, Santoni M, Flore G, Saba P, Pistis M, Gessa GL. Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex. Front Pharmacol 2020;11:588160. [PMID: 33071798 DOI: 10.3389/fphar.2020.588160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
274 Li K, Xue B, Wang Y, Wang X, Wang H, Wang X. Ventral mesencephalon astrocytes are more efficient than those of other regions in inducing dopaminergic neurons through higher expression level of TGF-beta3. J Mol Neurosci 2009;37:288-300. [PMID: 18982456 DOI: 10.1007/s12031-008-9146-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
275 Sarre S, Smolders I, Thorr� K, Ebinger G, Michotte Y. Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: A microdialysis study. J Neural Transmission 1997;104:1215-28. [DOI: 10.1007/bf01294722] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
276 Okazaki S, Boku S, Otsuka I, Horai T, Kimura A, Shimmyo N, Yamaki N, Hishimoto A. Clozapine increases macrophage migration inhibitory factor (MIF) expression via increasing histone acetylation of MIF promoter in astrocytes. J Psychiatr Res 2021;135:237-42. [PMID: 33508542 DOI: 10.1016/j.jpsychires.2021.01.033] [Reference Citation Analysis]
277 Rech RH. Neurolepsis: Anhedonia or blunting of emotional reactivity? Behav Brain Sci 1982;5:72-3. [DOI: 10.1017/s0140525x00010578] [Cited by in Crossref: 12] [Article Influence: 1.1] [Reference Citation Analysis]
278 Liebman J. Understanding neuroleptics: From “anhedonia” to “neuroleptothesia”. Behav Brain Sci 1982;5:64-5. [DOI: 10.1017/s0140525x00010487] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
279 Salgado JV, Vidal M, Oberling P, Graeff FG, Danion JM, Sandner G. Associative learning and latent inhibition in a conditioned suppression paradigm in humans. Behav Brain Res 2000;117:53-60. [PMID: 11099757 DOI: 10.1016/s0166-4328(00)00280-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
280 Katz RJ, Schmaltz K. Dopaminergic involvement in attention. A novel animal model. Prog Neuropsychopharmacol 1980;4:585-90. [PMID: 7220672 DOI: 10.1016/0364-7722(81)90099-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 1.1] [Reference Citation Analysis]
281 Lal S, Nair NPV, Thavundayil JX, Monks RC, Guyda H. Clonidine-induced growth hormone secretion in chronic schizophrenia. Acta Psychiatr Scand 1983;68:82-8. [DOI: 10.1111/j.1600-0447.1983.tb06985.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
282 McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends Neurosci 2019;42:205-20. [PMID: 30621912 DOI: 10.1016/j.tins.2018.12.004] [Cited by in Crossref: 162] [Cited by in F6Publishing: 115] [Article Influence: 81.0] [Reference Citation Analysis]
283 McClay JL, Vunck SA, Batman AM, Crowley JJ, Vann RE, Beardsley PM, van den Oord EJ. Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration. J Neuroimmune Pharmacol 2015;10:425-34. [PMID: 25850894 DOI: 10.1007/s11481-015-9605-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
284 Suzuki T, Moroji T. Cholecystokinin binding sites in the rat forebrain: effects of acute and chronic methamphetamine administration. J Neural Transmission 1989;77:181-95. [DOI: 10.1007/bf01248931] [Cited by in Crossref: 9] [Article Influence: 0.3] [Reference Citation Analysis]
285 Malmo RB, Malmo HP. Wise's neural model implicating the reticular formation: Some queries. Behav Brain Sci 1982;5:66-7. [DOI: 10.1017/s0140525x00010517] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
286 van Ree JM, Verhoeven WM, de Wied D. Chapter 23 Animal and clinical research on neuropeptides and schizophrenia. Neuropeptides and Brain Function. Elsevier; 1987. pp. 249-67. [DOI: 10.1016/s0079-6123(08)60213-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
287 Rivest R, Marsden CA. Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol. Br J Pharmacol 1991;104:234-8. [PMID: 1786513 DOI: 10.1111/j.1476-5381.1991.tb12412.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
288 Tochigi M, Otowa T, Hibino H, Kato C, Otani T, Umekage T, Utsumi T, Kato N, Sasaki T. Combined analysis of association between personality traits and three functional polymorphisms in the tyrosine hydroxylase, monoamine oxidase A, and catechol-O-methyltransferase genes. Neurosci Res 2006;54:180-5. [PMID: 16360899 DOI: 10.1016/j.neures.2005.11.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
289 Schulz S, van Kammen DP, Pickar D, Cohen MR, Naber D. Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients. Psychiatry Research 1982;7:171-8. [DOI: 10.1016/0165-1781(92)90090-p] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
290 Freed WJ, Zec RF. Criteria for ruling out sedation as an interpretation of neuroleptic effects. Behav Brain Sci 1982;5:57-9. [DOI: 10.1017/s0140525x00010426] [Cited by in Crossref: 10] [Article Influence: 0.9] [Reference Citation Analysis]
291 Merchant KM, Dobie DJ, Dorsa DM. Expression of the Proneurotensin Gene in the Rat Brain and Its Regulation by Antipsychotic Drugs. Ann NY Acad Sci 1992;668:54-69. [DOI: 10.1111/j.1749-6632.1992.tb27339.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
292 Popoli P, Reggio R, Pèzzola A, Scotti de Carolis A. The stimulation of cholecystokinin receptors in the rostral nucleus accumbens significantly antagonizes the EEG and behavioural effects induced by phencyclidine in rats. Psychopharmacology (Berl) 1995;120:156-61. [PMID: 7480547 DOI: 10.1007/BF02246188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
293 Rehfeld JF. Cholecystokinin. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 337-58. [DOI: 10.1002/cphy.cp060216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
294 Grenhoff J, Svensson TH. Clonidine modulates dopamine cell firing in rat ventral tegmental area. European Journal of Pharmacology 1989;165:11-8. [DOI: 10.1016/0014-2999(89)90765-6] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 2.7] [Reference Citation Analysis]
295 Weiner I. The Latent Inhibition Model of Schizophrenia. In: Myslobodsky MS, Weiner I, editors. Contemporary Issues in Modeling Psychopathology. Boston: Springer US; 2000. pp. 197-230. [DOI: 10.1007/978-1-4757-4860-4_12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
296 Lane RF, Blaha CD. Acute thioridazine stimulates mesolimbic but not nigrostriatal dopamine release: demonstration by in vivo electrochemistry. Brain Research 1987;408:317-20. [DOI: 10.1016/0006-8993(87)90396-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
297 Bunney BS. Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends in Neurosciences 1984;7:212-5. [DOI: 10.1016/s0166-2236(84)80013-2] [Cited by in Crossref: 94] [Article Influence: 2.5] [Reference Citation Analysis]
298 Maia-de-oliveira JP, Trzesniak C, Oliveira IR, Kempton MJ, Rezende TMND, Iego S, Baker GB, Dursun SM, Machado-de-sousa JP, Hallak JE. Nitric Oxide Plasma/Serum Levels In Patients With Schizophrenia: A Systematic Review And Meta-Analysis. Revista Brasileira de Psiquiatria 2012;34:149-62. [DOI: 10.1016/j.rbp.2012.07.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
299 Sellmann C, Pildaín LV, Schmitt A, Leonardi-essmann F, Durrenberger PF, Spanagel R, Arzberger T, Kretzschmar H, Zink M, Gruber O, Herrera-marschitz M, Reynolds R, Falkai P, Gebicke-haerter PJ, Matthäus F. Gene expression in superior temporal cortex of schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 2014;264:297-309. [DOI: 10.1007/s00406-013-0473-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
300 Soubrie P. Neuroleptic-induced anhedonia: Some psychopharmacological implications. Behav Brain Sci 1982;5:76-7. [DOI: 10.1017/s0140525x00010608] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
301 Baron J. Some thinking is irrational. Behav Brain Sci 1991;14:486-7. [DOI: 10.1017/s0140525x00070825] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
302 Csernansky JG, Prosser E, Kaplan J, Mahler E, Berger PA, Hollister LE. Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics. Biological Psychiatry 1986;21:632-42. [DOI: 10.1016/0006-3223(86)90124-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
303 Quitkin FM, Rifkin A, Tsuang MT, Kane JM, Klein DF. Can schizophrenia with premorbid asociality be genetically distinguished from the other forms of schizophrenia? Psychiatry Research 1980;2:99-105. [DOI: 10.1016/0165-1781(80)90010-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
304 Wheeler SC, Roth RH. Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment. Naunyn-Schmiedeberg's Arch Pharmacol 1980;312:151-9. [DOI: 10.1007/bf00569724] [Cited by in Crossref: 43] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Fiorella D, Helsley S, Rabin R, Winter J. Further investigations of the interactions of antipsychotics with the (−)2,5-dimethoxy-4-methylamphetamine (DOM) discriminative stimulus. Neuropharmacology 1997;36:1463-9. [DOI: 10.1016/s0028-3908(97)00121-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
306 Nemeroff CB, Luttinger D, Prange AJ. Neurotensin and Bombesin. In: Iversen LL, Iversen SD, Snyder SH, editors. Handbook of Psychopharmacology. Boston: Springer US; 1983. pp. 363-466. [DOI: 10.1007/978-1-4613-3515-3_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
307 Neill D. Problems of concept and vocabulary in the anhedonia hypothesis. Behav Brain Sci 1982;5:70-70. [DOI: 10.1017/s0140525x00010542] [Cited by in Crossref: 15] [Article Influence: 1.4] [Reference Citation Analysis]
308 Lochmann van Bennekom MW, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol 2013;27:327-36. [DOI: 10.1177/0269881113477709] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
309 Tsai S, Huang Y, Chang L, Yang Y, Sim C. Alterations in local cerebral glucose utilization in rats after chronic amphetamine administration without subsequent challenge. Psychiatry Research 1995;57:65-73. [DOI: 10.1016/0165-1781(95)02496-j] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
310 Trotman HD, Holtzman CW, Ryan AT, Shapiro DI, MacDonald AN, Goulding SM, Brasfield JL, Walker EF. The development of psychotic disorders in adolescence: a potential role for hormones. Horm Behav 2013;64:411-9. [PMID: 23998682 DOI: 10.1016/j.yhbeh.2013.02.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
311 Duncan GE, Leipzig JN, Mailman RB, Lieberman JA. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998;812:65-75. [PMID: 9813244 DOI: 10.1016/s0006-8993(98)00926-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
312 Kamata K, Rebec GV. Nigral reticulata neurons: potentiation of reponsiveness to amphetamine with long-term treatment. Brain Research 1985;332:188-93. [DOI: 10.1016/0006-8993(85)90406-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 0.6] [Reference Citation Analysis]
313 Ceulemans DLS, Gelders YG, Hoppenbrouwers MJA, Reyntjens AJM, Janssen PAJ. Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology 1985;85:329-32. [DOI: 10.1007/bf00428197] [Cited by in Crossref: 107] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
314 Rothschild AJ, Langlais PJ, Schatzberg AF, Miller MM, Saloman MS, Lerbinger JE, Cole JO, Bird ED. The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. Life Sciences 1985;36:2491-501. [DOI: 10.1016/0024-3205(85)90145-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 2.1] [Reference Citation Analysis]
315 Chiodo LA. Dopamine-containing neurons in the mammalian central nervous system: Electrophysiology and pharmacology. Neuroscience & Biobehavioral Reviews 1988;12:49-91. [DOI: 10.1016/s0149-7634(88)80073-3] [Cited by in Crossref: 190] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
316 Lambert G, Eisenhofer G, Jennings G, Esler M. Regional homovanillic acid production in humans. Life Sciences 1993;53:63-75. [DOI: 10.1016/0024-3205(93)90612-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
317 Heinz GH, Hill EF, Contrera JF. Dopamine and norepinephrine depletion in ring doves fed DDE, dieldrin, and Aroclor 1254. Toxicology and Applied Pharmacology 1980;53:75-82. [DOI: 10.1016/0041-008x(80)90383-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
318 Wachtel H, Turski L. Glutamate: a new target in schizophrenia? Trends Pharmacol Sci 1990;11:219-20. [PMID: 2166367 DOI: 10.1016/0165-6147(90)90243-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 2.1] [Reference Citation Analysis]
319 Salgado JV, Hetem LA, Vidal M, Graeff FG, Danion JM, Sandner G. Reduction of latent inhibition by d-amphetamine in a conditioned suppression paradigm in humans. Behavioural Brain Research 2000;117:61-7. [DOI: 10.1016/s0166-4328(00)00279-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
320 Beninger RJ. The behavioral function of dopamine. Behav Brain Sci 1982;5:55-6. [DOI: 10.1017/s0140525x00010402] [Cited by in Crossref: 14] [Article Influence: 1.3] [Reference Citation Analysis]
321 Verhoeven WM, van Ree JM, Westenberg HG, Krul JM, Brouwer GJ, Thijssen JH, de Wied D, van Praag HM, Ceulemans DL, Kahn R. Clinical, biochemical, and hormonal aspects of treatment with des-tyr1-gamma-endorphin in schizophrenia. Psychiatry Research 1984;11:329-46. [DOI: 10.1016/0165-1781(84)90006-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
322 Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology. 2010;35:881-892. [PMID: 19907417 DOI: 10.1038/npp.2009.176] [Cited by in Crossref: 167] [Cited by in F6Publishing: 121] [Article Influence: 13.9] [Reference Citation Analysis]
323 Anisman H. Anhedonia: Too much, too soon. Behav Brain Sci 1982;5:53-4. [DOI: 10.1017/s0140525x00010384] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
324 Rao ML, Gross G, Halaris A, Huber G, Marler M, Strebel B, Bräunig P. Hyperdopaminergia in schizophreniform psychosis: A chronobiological study. Psychiatry Research 1993;47:187-203. [DOI: 10.1016/0165-1781(93)90048-l] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
325 Haracz JL. A neural plasticity hypothesis of schizophrenia. Neuroscience & Biobehavioral Reviews 1984;8:55-71. [DOI: 10.1016/0149-7634(84)90020-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
326 Meltzer HY, Simonovic M, Sturgeon RD, Fang VS. Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels. Acta Psychiatrica Scandinavica 1981;63:100-21. [DOI: 10.1111/j.1600-0447.1981.tb00713.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 0.9] [Reference Citation Analysis]
327 Müller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother 2008;8:1037-48. [PMID: 18590475 DOI: 10.1586/14737175.8.7.1037] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
328 Wiener JM, Perlmutter IR, Greenhill LL, Chambers W, Kestenbaum CJ. Childhood Schizophrenia: Theoretical and Treatment Issues. Journal of the American Academy of Child & Adolescent Psychiatry 1989;28:956-62. [DOI: 10.1097/00004583-198911000-00025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
329 Lal S. Apomorphine in the evaluation of dopaminergic function in man. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1988;12:117-64. [DOI: 10.1016/0278-5846(88)90033-4] [Cited by in Crossref: 90] [Cited by in F6Publishing: 72] [Article Influence: 2.7] [Reference Citation Analysis]
330 van Ree JM, Gaffori O, Kiraly I. γ-endorphin and Nα-acetyl-γ-endorphin interfere with distinct dopaminergic systems in the nucleus accumbens via opioid and non-opioid mechanisms. Life Sciences 1984;34:1317-24. [DOI: 10.1016/0024-3205(84)90002-x] [Cited by in Crossref: 15] [Article Influence: 0.4] [Reference Citation Analysis]
331 German DC. Dopamine neurons, reward and behavior. Behav Brain Sci 1982;5:59-60. [DOI: 10.1017/s0140525x00010438] [Cited by in Crossref: 10] [Article Influence: 0.9] [Reference Citation Analysis]
332 Moon SY, Kim M, Lho SK, Oh S, Kim SH, Kwon JS. Systematic Review of the Neural Effect of Electroconvulsive Therapy in Patients with Schizophrenia: Hippocampus and Insula as the Key Regions of Modulation. Psychiatry Investig 2021;18:486-99. [PMID: 34218638 DOI: 10.30773/pi.2020.0438] [Reference Citation Analysis]
333 Tomasik J, Schwarz E, Lago SG, Rothermundt M, Leweke FM, van Beveren NJM, Guest PC, Rahmoune H, Steiner J, Bahn S. Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain Behav Immun 2016;52:178-86. [PMID: 26541453 DOI: 10.1016/j.bbi.2015.10.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
334 Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 1999;843:171-83. [PMID: 10528123 DOI: 10.1016/s0006-8993(99)01776-x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
335 Roth JA, Feor K. Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochemical Pharmacology 1978;27:1606-8. [DOI: 10.1016/0006-2952(78)90493-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 0.8] [Reference Citation Analysis]
336 Benussi A, Dell'Era V, Cantoni V, Cotelli MS, Cosseddu M, Spallazzi M, Alberici A, Padovani A, Borroni B. Neurophysiological Correlates of Positive and Negative Symptoms in Frontotemporal Dementia. J Alzheimers Dis 2020;73:1133-42. [PMID: 31884481 DOI: 10.3233/JAD-190986] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
337 Ridley RM, Baker HF. Stereotypy in monkeys and humans. Psychol Med 1982;12:61-72. [DOI: 10.1017/s0033291700043294] [Cited by in Crossref: 99] [Cited by in F6Publishing: 11] [Article Influence: 8.3] [Reference Citation Analysis]
338 Pizzolato G, Soncrant TT, Larson DM, Rapoport SI. Reduced metabolic response of the rat brain to haloperidol after chronic treatment. Brain Research 1985;337:1-9. [DOI: 10.1016/0006-8993(85)91604-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
339 Wechsler LR, Savaki HE, Sokoloff L. EFFECTS OF d- AND l-AMPHETAMINE ON LOCAL CEREBRAL GLUCOSE UTILIZATION IN THE CONSCIOUS RAT. J Neurochem 1979;32:15-22. [DOI: 10.1111/j.1471-4159.1979.tb04504.x] [Cited by in Crossref: 150] [Cited by in F6Publishing: 123] [Article Influence: 3.6] [Reference Citation Analysis]
340 Thermos K, Murphy RB, Schuster DI. Photoincorporation of [3H]-chloropromazine into a solubilized bovine striatal preparation. Biochemical and Biophysical Research Communications 1982;106:1469-77. [DOI: 10.1016/0006-291x(82)91279-7] [Cited by in Crossref: 4] [Article Influence: 0.1] [Reference Citation Analysis]
341 Hawken ER, Beninger RJ. The amphetamine sensitization model of schizophrenia symptoms and its effect on schedule-induced polydipsia in the rat. Psychopharmacology 2014;231:2001-8. [DOI: 10.1007/s00213-013-3345-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
342 Capuano B, Crosby IT, Forsyth CM, Mcrobb FM, Moudretski VV, Taylor DA, Vom A, Yuriev E. New hybrids of clozapine and haloperidol and their isosteric analogues: synthesis, X-ray crystallography, conformational analysis and preliminary pharmacological evaluation. Struct Chem 2010;21:613-28. [DOI: 10.1007/s11224-010-9591-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
343 Palumbo PA, Winter JC. Interactions of clozapine with the stimulus effects of DOM and LSD. Pharmacol Biochem Behav 1994;49:115-20. [PMID: 7816860 DOI: 10.1016/0091-3057(94)90464-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
344 Tyler MW, Zaldivar-Diez J, Haggarty SJ. Classics in Chemical Neuroscience: Haloperidol. ACS Chem Neurosci 2017;8:444-53. [PMID: 28170220 DOI: 10.1021/acschemneuro.7b00018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 7.8] [Reference Citation Analysis]
345 Meltzer HY. Dopamine autoreceptor stimulation: Clinical significance. Pharmacology Biochemistry and Behavior 1982;17:1-10. [DOI: 10.1016/0091-3057(82)90504-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis]
346 Marini S, De Berardis D, Vellante F, Santacroce R, Orsolini L, Valchera A, Girinelli G, Carano A, Fornaro M, Gambi F, Martinotti G, Di Giannantonio M. Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Mediators Inflamm 2016;2016:3476240. [PMID: 27524864 DOI: 10.1155/2016/3476240] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
347 Lal S, Tesfaye Y, Thavundayil JX, Thompson TR, Kiely ME, Nair N, Grassino A, Dubrovsky B. Apomorphine: Clinical studies on erectile impotence and yawning. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1989;13:329-39. [DOI: 10.1016/0278-5846(89)90122-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
348 Brennan MD, Condra J. Transmission disequilibrium suggests a role for the sulfotransferase-4A1 gene in schizophrenia. Am J Med Genet 2005;139B:69-72. [DOI: 10.1002/ajmg.b.30222] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
349 Bonoldi I, Howes OD. Presynaptic dopaminergic function: implications for understanding treatment response in psychosis. CNS Drugs 2014;28:649-63. [PMID: 24919790 DOI: 10.1007/s40263-014-0177-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
350 Devoto P, Flore G, Vacca G, Pira L, Arca A, Casu MA, Pani L, Gessa GL. Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacology (Berl) 2003;167:79-84. [PMID: 12632247 DOI: 10.1007/s00213-002-1381-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
351 Van Oot PH, Lane TW, Borkovec TD. Sleep Disturbances. In: Adams HE, Sutker PB, editors. Comprehensive Handbook of Psychopathology. Boston: Springer US; 1984. pp. 683-723. [DOI: 10.1007/978-1-4615-6681-6_24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
352 Guterman Y, Josiassen RC, Bashore TE, Johnson M, Lubow RE. Latent inhibition effects reflected in event-related brain potentials in healthy controls and schizophrenics. Schizophrenia Research 1996;20:315-26. [DOI: 10.1016/0920-9964(95)00086-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
353 Doherty JD, Simonovic M, So R, Meltzer HY. The effect of phencyclidine on dopamine synthesis and metabolism in rat striatum. European Journal of Pharmacology 1980;65:139-49. [DOI: 10.1016/0014-2999(80)90386-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 1.7] [Reference Citation Analysis]
354 Smidt MP, Smits SM, Burbach JH. Molecular mechanisms underlying midbrain dopamine neuron development and function. European Journal of Pharmacology 2003;480:75-88. [DOI: 10.1016/j.ejphar.2003.08.094] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
355 Kokkinidis L, Anisman H. Amphetamine psychosis and schizophrenia: A dual model. Neuroscience & Biobehavioral Reviews 1981;5:449-61. [DOI: 10.1016/0149-7634(81)90015-4] [Cited by in Crossref: 92] [Cited by in F6Publishing: 64] [Article Influence: 2.3] [Reference Citation Analysis]
356 Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997;37:75-86. [PMID: 9285246 DOI: 10.1016/s0162-3109(97)00037-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
357 Stahl SM. Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr 2016;21:355-9. [DOI: 10.1017/s1092852916000602] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 4.4] [Reference Citation Analysis]
358 Fields JZ, Gordon JH. Estrogen inhibits the dopaminergic supersensitivity induced by neuroleptics. Life Sciences 1982;30:229-34. [DOI: 10.1016/0024-3205(82)90503-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 1.3] [Reference Citation Analysis]
359 Wan W, Ennulat DJ, Cohen BM. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Research 1995;688:95-104. [DOI: 10.1016/0006-8993(95)00544-z] [Cited by in Crossref: 62] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
360 Martino M, Magioncalda P, Yu H, Li X, Wang Q, Meng Y, Deng W, Li Y, Li M, Ma X, Lane T, Duncan NW, Northoff G, Li T. Abnormal Resting-State Connectivity in a Substantia Nigra-Related Striato-Thalamo-Cortical Network in a Large Sample of First-Episode Drug-Naïve Patients With Schizophrenia. Schizophr Bull 2018;44:419-31. [PMID: 28605528 DOI: 10.1093/schbul/sbx067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 14.7] [Reference Citation Analysis]
361 Meyer U, Feldon J. Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) 2009;206:587-602. [PMID: 19277608 DOI: 10.1007/s00213-009-1504-9] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
362 Schaeffer JL, Ross RG. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry. 2002;41:538-545. [PMID: 12014786 DOI: 10.1097/00004583-200205000-00011] [Cited by in Crossref: 72] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
363 Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR. Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse 2002;46:129-39. [DOI: 10.1002/syn.10116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
364 Weinberger D, Wyatt R. CEREBRAL VENTRICULAR SIZE: A BIOLOGICAL MARKER FOR SUB-TYPING CHRONIC SCHIZOPHRENIA. Biological Markers in Psychiatry and Neurology. Elsevier; 1982. pp. 505-12. [DOI: 10.1016/b978-0-08-027987-9.50054-8] [Cited by in Crossref: 18] [Article Influence: 0.5] [Reference Citation Analysis]
365 Altar C. Cholecystokinin receptor subtypes and neuromodulation. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1989;13:381-93. [DOI: 10.1016/0278-5846(89)90127-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
366 Geldenhuys WJ, Kuzenko SR, Simmons MA. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. J Med Chem 2010;53:8080-8. [PMID: 21047106 DOI: 10.1021/jm1010012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
367 Lidow M, Williams G, Goldman-rakic P. The cerebral cortex: a case for a common site of action of antipsychotics. Trends in Pharmacological Sciences 1998;19:136-40. [DOI: 10.1016/s0165-6147(98)01186-9] [Cited by in Crossref: 124] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
368 Wise RA. Hypotheses of neuroleptic action: Levels of progress. Behav Brain Sci 1982;5:78-87. [DOI: 10.1017/s0140525x00010621] [Cited by in Crossref: 10] [Article Influence: 0.9] [Reference Citation Analysis]
369 Peleg-Raibstein D, Feldon J. Effects of dorsal and ventral hippocampal NMDA stimulation on nucleus accumbens core and shell dopamine release. Neuropharmacology 2006;51:947-57. [PMID: 16876207 DOI: 10.1016/j.neuropharm.2006.06.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
370 Chana G, Bousman CA, Money TT, Gibbons A, Gillett P, Dean B, Everall IP. Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Front Cell Neurosci 2013;7:95. [PMID: 23805071 DOI: 10.3389/fncel.2013.00095] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
371 Kleinman JE, Bridge P, Karoum F, Speciale S, Staub R, Zalcman S, Gillin JC, Wyatt RJ. CATECHOLAMINES AND METABOLITES IN THE BRAINS OF PSYCHOTICS AND NORMALS: POST-MORTEM STUDIES. Catecholamines: Basic and Clinical Frontiers. Elsevier; 1979. pp. 1845-7. [DOI: 10.1016/b978-1-4832-8363-0.50566-8] [Cited by in Crossref: 8] [Article Influence: 0.2] [Reference Citation Analysis]
372 Essali A, Ali G. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Syst Rev 2012;:CD004162. [PMID: 22336800 DOI: 10.1002/14651858.CD004162.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
373 Asnis GM, Sachar EJ, Halbreich U, Ostrow LC, Nathan R, Halpern FS. The prolactin-stimulating potency of reserpine in man. Psychiatry Research 1981;5:39-45. [DOI: 10.1016/0165-1781(81)90059-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
374 Freed WJ, Cannon-spoor H, Rodgers CR. Attenuation of the behavioral response to quisqualic acid and glutamic acid diethyl ester by chronic haloperidol administration. Life Sciences 1989;44:1303-8. [DOI: 10.1016/0024-3205(89)90368-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
375 Cohen JD, Servan-schreiber D. A Neural Network Model of Disturbances in the Processing of Context in Schizophrenia. Psychiatric Annals 1992;22:131-6. [DOI: 10.3928/0048-5713-19920301-09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
376 van Ree JM, Verhoeven WM, Claas FH, de Wied D. Antipsychotic Action of γ‐Type Endorphins: Animal and Human Studies. Elsevier; 1986. pp. 221-35. [DOI: 10.1016/s0079-6123(08)60653-6] [Cited by in Crossref: 13] [Article Influence: 0.4] [Reference Citation Analysis]
377 Bobo WV, Shelton RC. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. Expert Rev Neurother 2010;10:1637-58. [PMID: 20977322 DOI: 10.1586/ern.10.143] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
378 Gil-da-Costa R, Stoner GR, Fung R, Albright TD. Nonhuman primate model of schizophrenia using a noninvasive EEG method. Proc Natl Acad Sci U S A 2013;110:15425-30. [PMID: 23959894 DOI: 10.1073/pnas.1312264110] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 11.8] [Reference Citation Analysis]
379 Huberman A, Turek VF, Carlisle HJ. Clozapine does not induce a motor impairment in operant responding for heat reinforcement. Pharmacology Biochemistry and Behavior 2000;67:307-12. [DOI: 10.1016/s0091-3057(00)00364-6] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
380 Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 1994;91:11651-4. [PMID: 7972118 DOI: 10.1073/pnas.91.24.11651] [Cited by in Crossref: 231] [Cited by in F6Publishing: 192] [Article Influence: 8.6] [Reference Citation Analysis]
381 Chagraoui A, Thibaut F, Skiba M, Thuillez C, Bourin M. 5-HT2C receptors in psychiatric disorders: A review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016;66:120-35. [DOI: 10.1016/j.pnpbp.2015.12.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 36] [Article Influence: 11.2] [Reference Citation Analysis]
382 Sabioni P, Ramos AC, Galduróz JC. The effectiveness of treatments for cocaine dependence in schizophrenic patients: a systematic review. Curr Neuropharmacol 2013;11:484-90. [PMID: 24403872 DOI: 10.2174/1570159X11311050003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
383 Crosson B. Subcortical functions in language: A working model. Brain and Language 1985;25:257-92. [DOI: 10.1016/0093-934x(85)90085-9] [Cited by in Crossref: 230] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
384 Nair N, Lal S, Bloom D. Cholecystokinin and Schizophrenia. Elsevier; 1986. pp. 237-58. [DOI: 10.1016/s0079-6123(08)60654-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
385 Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS. Mechanisms of action of atypical antipsychotic drugs. Schizophrenia Research 1991;4:121-56. [DOI: 10.1016/0920-9964(91)90030-u] [Cited by in Crossref: 164] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
386 Lakhan SE, Caro M, Hadzimichalis N. NMDA Receptor Activity in Neuropsychiatric Disorders. Front Psychiatry 2013;4:52. [PMID: 23772215 DOI: 10.3389/fpsyt.2013.00052] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 8.9] [Reference Citation Analysis]
387 Gray JA, Buhusi CV, Schmajuk N. The Transition from Automatic to Controlled Processing. Neural Networks 1997;10:1257-68. [DOI: 10.1016/s0893-6080(97)00058-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
388 Moore SC, Sellen JL. Jumping to conclusions: a network model predicts schizophrenic patients' performance on a probabilistic reasoning task. Cogn Affect Behav Neurosci 2006;6:261-9. [PMID: 17458441 DOI: 10.3758/cabn.6.4.261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
389 Fiorella D, Helsley S, Rabin R, Winter J. The interactions of typical and atypical antipsychotics with the (−)2,5,-dimethoxy-4-methamphetamine (DOM) discriminative stimulus. Neuropharmacology 1995;34:1297-303. [DOI: 10.1016/0028-3908(95)00101-b] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
390 Tomasella E, Bechelli L, Ogando MB, Mininni C, Di Guilmi MN, De Fino F, Zanutto S, Elgoyhen AB, Marin-Burgin A, Gelman DM. Deletion of dopamine D2 receptors from parvalbumin interneurons in mouse causes schizophrenia-like phenotypes. Proc Natl Acad Sci U S A 2018;115:3476-81. [PMID: 29531031 DOI: 10.1073/pnas.1719897115] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
391 Orzi F, Dow-edwards D, Jehle J, Kennedy C, Sokoloff L. Comparative Effects of Acute and Chronic Administration of Amphetamine on Local Cerebral Glucose Utilization in the Conscious Rat. J Cereb Blood Flow Metab 1983;3:154-60. [DOI: 10.1038/jcbfm.1983.22] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 10.2] [Reference Citation Analysis]
392 Guitart X, Codony X, Ballarín M, Dordal A, Farré AJ. E-5842: A New Potent and Preferential Sigma Ligand. Preclinical Pharmacological Profile. CNS Drug Reviews 1998;4:201-24. [DOI: 10.1111/j.1527-3458.1998.tb00065.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
393 Caravaggio F, Borlido C, Wilson A, Graff-Guerrero A. Examining endogenous dopamine in treated schizophrenia using [¹¹C]-(+)-PHNO positron emission tomography: A pilot study. Clin Chim Acta 2015;449:60-2. [PMID: 25814099 DOI: 10.1016/j.cca.2015.03.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
394 Fields JZ, Reisine TD, Yamamura HI. Biochemical demonstration of dopaminergic receptors in rat and human brain using [3H]spiroperidol. Brain Research 1977;136:578-84. [DOI: 10.1016/0006-8993(77)90084-1] [Cited by in Crossref: 263] [Cited by in F6Publishing: 226] [Article Influence: 6.0] [Reference Citation Analysis]
395 Liégeois J, Ichikawa J, Meltzer HY. 5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Research 2002;947:157-65. [DOI: 10.1016/s0006-8993(02)02620-3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
396 Nishiyama K, Suzuki H, Maruyama M, Yoshihara T, Ohta H. Genetic deletion of GPR52 enhances the locomotor-stimulating effect of an adenosine A2A receptor antagonist in mice: A potential role of GPR52 in the function of striatopallidal neurons. Brain Res 2017;1670:24-31. [PMID: 28583861 DOI: 10.1016/j.brainres.2017.05.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
397 Keulen S, Verhoeven J, De Witte E, De Page L, Bastiaanse R, Mariën P. Foreign Accent Syndrome As a Psychogenic Disorder: A Review. Front Hum Neurosci 2016;10:168. [PMID: 27199699 DOI: 10.3389/fnhum.2016.00168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
398 Carlton PL, Manowitz P. Dopamine and schizophrenia: An analysis of the theory. Neuroscience & Biobehavioral Reviews 1984;8:137-51. [DOI: 10.1016/0149-7634(84)90029-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 0.9] [Reference Citation Analysis]
399 Valenti O, Grace AA. Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway. Int J Neuropsychopharmacol 2010;13:845-60. [PMID: 19751544 DOI: 10.1017/S1461145709990599] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
400 Lacroix D, Chaput Y, Rodriguez J, Filion M, Morrison D, St-denis P, Albert J. Quantified EEG changes associated with a positive clinical response to clozapine in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1995;19:861-76. [DOI: 10.1016/0278-5846(95)00116-d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
401 Burbach JH. Genetic pathways in the developmental specification of hypothalamic neuropeptide and midbrain catecholamine systems. European Journal of Pharmacology 2000;405:55-62. [DOI: 10.1016/s0014-2999(00)00541-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
402 Bohus B. Neuropeptides in Brain Functions and Dysfunctions. International Journal of Mental Health 2015;9:6-44. [DOI: 10.1080/00207411.1980.11448861] [Cited by in Crossref: 39] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
403 Hernandez L, Baptista T, Hoebel BG. Neurochemical effects of chronic haloperidol and lithium assessed by brain microdialysis in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1990;14:S17-35. [DOI: 10.1016/0278-5846(90)90084-t] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
404 Lynch MR. Schizophrenia and the D1 receptor: Focus on negative symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1992;16:797-832. [DOI: 10.1016/0278-5846(92)90102-k] [Cited by in Crossref: 39] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
405 Meltzer H, So R, Miller R, Fang V. Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of 3H-spiroperidol in the rat pituitary and striatum with effects on rat prolactin secretion. Life Sciences 1979;25:573-83. [DOI: 10.1016/0024-3205(79)90551-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 1.3] [Reference Citation Analysis]
406 Khan ZU, Koulen P, Rubinstein M, Grandy DK, Goldman-Rakic PS. An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proc Natl Acad Sci U S A 2001;98:1964-9. [PMID: 11172059 DOI: 10.1073/pnas.98.4.1964] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 5.4] [Reference Citation Analysis]
407 Tejedor-Real P, Vogel R, Mallet J, Biguet NF. Gi/Go protein-dependent presynaptic mechanisms are involved in clozapine-induced down-regulation of tyrosine hydroxylase in PC12 cells. J Neurosci Res 2005;81:739-45. [PMID: 15983997 DOI: 10.1002/jnr.20585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
408 Gray NS, Pickering AD, Gray JA. Psychoticism and dopamine D2 binding in the basal ganglia using single photon emission tomography. Personality and Individual Differences 1994;17:431-4. [DOI: 10.1016/0191-8869(94)90289-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
409 van Kammen DP, Sternberg DE. Cerebrospinal Fluid Studies in Schizophrenia. In: Wood JH, editor. Neurobiology of Cerebrospinal Fluid 1. Boston: Springer US; 1980. pp. 719-42. [DOI: 10.1007/978-1-4684-1039-6_48] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
410 Lambert GW, Horne M, Kalff V, Kelly MJ, Turner AG, Cox HS, Jennings GL, Esler MD. Central nervous system noradrenergic and dopaminergic turnover in response to acute neuroleptic challenge. Life Sciences 1995;56:1545-55. [DOI: 10.1016/0024-3205(95)00120-u] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
411 Gracey DJ, Bell R, King DJ. PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat. Pharmacol Biochem Behav 2000;65:459-63. [PMID: 10683486 DOI: 10.1016/s0091-3057(99)00227-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
412 Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci 2015;69:243-58. [PMID: 25296946 DOI: 10.1111/pcn.12242] [Cited by in Crossref: 96] [Cited by in F6Publishing: 59] [Article Influence: 13.7] [Reference Citation Analysis]
413 Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res 1993;46:139-49. [PMID: 8483973 DOI: 10.1016/0165-1781(93)90016-a] [Cited by in Crossref: 47] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
414 Krieckhaus EE, Donahoe JW, Morgan MA. Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol Psychiatry 1992;31:560-70. [PMID: 1349833 DOI: 10.1016/0006-3223(92)90242-r] [Cited by in Crossref: 54] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
415 Clark D, Chiodo LA. Electrophysiological and pharmacological characterization of identified nigrostriatal and mesoaccumbens dopamine neurons in the rat. Synapse 1988;2:474-85. [DOI: 10.1002/syn.890020503] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 1.8] [Reference Citation Analysis]
416 Minabe Y, Shirayama Y, Hashimoto K, Routledge C, Hagan JJ, Ashby CR. Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse 2004;52:20-8. [DOI: 10.1002/syn.20002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
417 Hoebel BG, Monaco AP, Hernandez L, Aulisi EF, Stanley BG, Lenard L. Self-injection of amphetamine directly into the brain. Psychopharmacology (Berl) 1983;81:158-63. [PMID: 6415748 DOI: 10.1007/BF00429012] [Cited by in Crossref: 265] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
418 Stelmack RM, Pivik R. Extraversion and the effect of exercise on spinal motoneuronal excitability. Personality and Individual Differences 1996;21:69-76. [DOI: 10.1016/0191-8869(96)00034-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
419 Robinson D, Mayerhoff D, Alvir J, Cooper T, Lieberman J. Mood responses of remitted schizophrenics to methylphenidate infusion. Psychopharmacology 1991;105:247-52. [DOI: 10.1007/bf02244317] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
420 Belardetti F. Evolving therapeutic indications for N-type calcium channel blockers: from chronic pain to alcohol abuse. Future Med Chem 2010;2:791-802. [PMID: 21426203 DOI: 10.4155/fmc.10.30] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
421 Huff F, Reiter CT, Rosen J, Peters J, van Kammen DP. No effect of haloperidol on cerebrospinal fluid acetylcholinesterase in patients with schizophrenia. Biological Psychiatry 1988;24:701-4. [DOI: 10.1016/0006-3223(88)90145-x] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
422 Ichikawa J, Chung Y, Li Z, Dai J, Meltzer HY. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Research 2002;958:176-84. [DOI: 10.1016/s0006-8993(02)03692-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
423 Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72. [PMID: 3790642 DOI: 10.1016/0006-3223(87)90131-4] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 2.4] [Reference Citation Analysis]
424 Frey WH 2nd, Senogles SE, Heston LL, Tuason VB, Nicol SE. Catecholamine-sensitive guanylate cyclase from human caudate nucleus. J Neurochem 1980;35:1418-30. [PMID: 6108353 DOI: 10.1111/j.1471-4159.1980.tb09018.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
425 Megens AAHP, Awouters FHL, Schotte A, Meert TF, Dugovic C, Niemegeers CJE, Leysen JE. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 1994;114:9-23. [DOI: 10.1007/bf02245439] [Cited by in Crossref: 138] [Cited by in F6Publishing: 21] [Article Influence: 5.1] [Reference Citation Analysis]
426 Moroji T, Hagino Y. A behavioral pharmacological study on CCK-8 related peptides in mice. Neuropeptides 1986;8:273-86. [DOI: 10.1016/0143-4179(86)90054-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.5] [Reference Citation Analysis]
427 Xu J, Kurup P, Nairn AC, Lombroso PJ. Synaptic NMDA Receptor Activation Induces Ubiquitination and Degradation of STEP61. Mol Neurobiol 2018;55:3096-111. [PMID: 28466270 DOI: 10.1007/s12035-017-0555-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
428 Kovelman JA, Scheibel AB. Biological substrates of schizophrenia. Acta Neurologica Scandinavica 1986;73:1-32. [DOI: 10.1111/j.1600-0404.1986.tb03237.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
429 McGuire JL, Hammond JH, Yates SD, Chen D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Altered serine/threonine kinase activity in schizophrenia. Brain Res 2014;1568:42-54. [PMID: 24780530 DOI: 10.1016/j.brainres.2014.04.029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
430 Schlemmer R, Jackson J, Preston KL, Bederka JP, Garver DL, Davis JM. Phencyclidine-induced stereotyped behavior in monkeys: Antagonism by pimozide. European Journal of Pharmacology 1978;52:379-84. [DOI: 10.1016/0014-2999(78)90293-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 1.4] [Reference Citation Analysis]
431 Gacsályi I, Nagy K, Pallagi K, Lévay G, Hársing LG Jr, Móricz K, Kertész S, Varga P, Haller J, Gigler G, Szénási G, Barkóczy J, Bíró J, Spedding M, Antoni FA. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology 2013;64:254-63. [PMID: 22824189 DOI: 10.1016/j.neuropharm.2012.07.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
432 Hurd YL, Lindefors N, Brodin E, Brene´ S, Persson H, Ungerstedt U, Ho¨kfelt T. Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission. Brain Research 1992;578:317-26. [DOI: 10.1016/0006-8993(92)90264-a] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
433 Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99 Suppl:S18-27. [PMID: 2682729 DOI: 10.1007/BF00442554] [Cited by in Crossref: 388] [Cited by in F6Publishing: 64] [Article Influence: 12.1] [Reference Citation Analysis]
434 Howes OD, McCutcheon R, Owen MJ, Murray RM. The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. Biol Psychiatry. 2017;81:9-20. [PMID: 27720198 DOI: 10.1016/j.biopsych.2016.07.014] [Cited by in Crossref: 256] [Cited by in F6Publishing: 147] [Article Influence: 51.2] [Reference Citation Analysis]
435 Duan X, Zhang M, Zhang X, Wang F, Lei M. Molecular modeling and docking study on dopamine D2-like and serotonin 5-HT2A receptors. Journal of Molecular Graphics and Modelling 2015;57:143-55. [DOI: 10.1016/j.jmgm.2015.01.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
436 Gracey DJ, Bell R, King DJ. Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:497-504. [PMID: 11999900 DOI: 10.1016/s0278-5846(01)00296-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
437 Nemeroff CB. The interaction of neurotensin with dopaminergic pathways in the central nervous system: Basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. Psychoneuroendocrinology 1986;11:15-37. [DOI: 10.1016/0306-4530(86)90029-6] [Cited by in Crossref: 152] [Cited by in F6Publishing: 139] [Article Influence: 4.3] [Reference Citation Analysis]
438 Schneider SJ. Multiple measures of hemispheric dysfunction in schizophrenia and depression. Psychol Med 1983;13:287-97. [DOI: 10.1017/s003329170005090x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
439 Schuster DI, Holden WL, Narula AP, Murphy RB. Irreversible blockade of striatal dopamine receptors in vivo by a derivative of α-flupenthixol. European Journal of Pharmacology 1982;77:313-6. [DOI: 10.1016/0014-2999(82)90134-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
440 White KE, Cummings JL. Schizophrenia and Alzheimer’s disease: clinical and pathophysiologic analogies. Compr Psychiatry. 1996;37:188-195. [PMID: 8732586 DOI: 10.1016/s0010-440x(96)90035-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
441 Nestoros JN, Suranyl-cadotte BE, Spees RC, Schwartz G, Vasavan Nair N. Diazepam in high doses is effective in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1982;6:513-6. [DOI: 10.1016/s0278-5846(82)80141-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
442 Nestoros JN, Nair NPV, Pulman JR, Schwartz G, Bloom D. High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients. Psychopharmacology 1983;81:42-7. [DOI: 10.1007/bf00439272] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
443 Krieger NR. Neurochemistry of the Olfactory Tubercle. Biochemistry of Taste and Olfaction. Elsevier; 1981. pp. 417-41. [DOI: 10.1016/b978-0-12-154450-8.50029-x] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
444 Fritze S, Sambataro F, Kubera KM, Bertolino AL, Topor CE, Wolf RC, Hirjak D. Neurological soft signs in schizophrenia spectrum disorders are not confounded by current antipsychotic dosage. European Neuropsychopharmacology 2020;31:47-57. [DOI: 10.1016/j.euroneuro.2019.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
445 Stahl SM, Meltzer HY. The human platelet as a model for the dopaminergic neuron: Kinetic and pharmacologic properties and the role of amine storage granules. Experimental Neurology 1978;59:1-15. [DOI: 10.1016/0014-4886(78)90196-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
446 Maas JW, Hattox SE, Landis D, Roth RH. A direct method for studying 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) production by brain in awake animals. European Journal of Pharmacology 1977;46:221-8. [DOI: 10.1016/0014-2999(77)90337-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 1.3] [Reference Citation Analysis]
447 Tandon R. Cholinergic aspects of schizophrenia. Br J Psychiatry 1999;174:7-11. [DOI: 10.1192/s0007125000293586] [Cited by in Crossref: 77] [Article Influence: 25.7] [Reference Citation Analysis]
448 Kulkarni J, Horne M, Butler E, Keks N, Copolov D. Psychotic symptoms resulting from intraventricular infusion of dopamine in Parkinson's disease. Biological Psychiatry 1992;31:1225-7. [DOI: 10.1016/0006-3223(92)90342-w] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
449 Sinnamon HM. The reward-effort model: An economic framework for examining the mechanism of neuroleptic action. Behav Brain Sci 1982;5:73-5. [DOI: 10.1017/s0140525x0001058x] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
450 Baldessarini RJ. Dopamine Receptors and Clinical Medicine. In: Neve KA, Neve RL, editors. The Dopamine Receptors. Totowa: Humana Press; 1997. pp. 457-98. [DOI: 10.1007/978-1-4757-2635-0_15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
451 Hart WG. Reply to a case report by Ian Sale and Henry Kristall--March issue. Aust N Z J Psychiatry 1978;12:136-7. [PMID: 278605 DOI: 10.3109/00048677809159608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
452 Fryar-Williams S, Strobel JE. Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res 2015;3:3. [PMID: 25729574 DOI: 10.1186/s40364-015-0028-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
453 Schlumberger C, Pietraszek M, Gravius A, Klein KU, Greco S, Morè L, Danysz W. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol 2009;623:73-83. [PMID: 19765575 DOI: 10.1016/j.ejphar.2009.09.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
454 Weiser M, Reichenberg A, Werbeloff N, Kravitz E, Halperin D, Lubin G, Shmushkevitch M, Yoffe R, Addington J, Davidson M. Self-report of family functioning and risk for psychotic disorders in male adolescents with behavioural disturbances. Acta Psychiatr Scand 2008;117:225-31. [DOI: 10.1111/j.1600-0447.2007.01143.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
455 Kamata K, Kameyama T. Effects of Methamphetamine on Dopamine Cells in the Substantia Nigra Pars Compacta and the Ventral Tegmental Area. Japanese Journal of Pharmacology 1985;38:231-4. [DOI: 10.1254/jjp.38.231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
456 Ridley RM, Baker HF, Owen F, Cross AJ, Crow TJ. Behavioural and biochemical effects of chronic amphetamine treatment in the vervet monkey. Psychopharmacology (Berl) 1982;78:245-51. [PMID: 6130556 DOI: 10.1007/BF00428159] [Cited by in Crossref: 58] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]